Psychotropic drugs in Portugal from 2016 to 2019: a nationwide pharmacoepidemiological profile

Luís Madeira^a, Guilherme Queiroz^b, and Rui Henriques^{c,*}

Abstract

Background: The prescription of psychotropic medication is rising in Europe along the last decade. Exploring consumption patterns in pre-pandemic times in Portugal, as well as relevant socio-demographic determinants, can help establish comparisons with worldwide patterns and support public health policies for mental health.

Methods: Descriptive, non-comparative cohort study, comprising full nationwide drug prescription records in Portugal along antidepressant, antipsychotic, and anxiolytic classes. Statistical analysis of prescription and consumption patterns according to reference dosages and guided by several criteria, including active substance, demographics, geography, associated medical specialty, and incurred costs.

Results: An increase of 29.6% and 34.7% in the consumption of antipsychotics and antidepressants between 2016 and 2019 is highlighted, reasonably accompanied by an increase of 37M Eur in total expenditure (>20M Eur in public copay) for these classes of drugs. Disparities in sociodemographic and geographical incidence are identified. Amongst other pivotal results, we further observed that 64% of psychotropic drug prescriptions are undertaken by general practitioners, while only 21% undertaken by neurological and psychiatric specialties.

Conclusion: Nationwide patterns of psychotropic drug prescription in Portugal reveal notable trends and determinants, establishing a reference point for cross-regional studies and being currently assessed at a national level to establish psychosocial initiatives and guidelines for the clinical practice and medical training.

Keywords: psychopharmacology, epidemiology, drug prescription and consumption, psychotropic drugs, antidepressants, antipsychotics, anxiolytics, mental health

Novelty: To our knowledge, first Portuguese psychopharmacoepidemiological study assessing: 1) economic correlates; 2) prescription patterns by medical specialty; 3) adherence rates and geographical determinants; 4) consumption patterns by active substance; and 5) systematic trends for the pre-pandemic period.

1 Introduction

Psychiatry disorders are among the leading chronic non-communicable diseases in the world (IHME 2022), and Portugal is no exception, with a prevalence of 18.4% of mental illness. The commitment to deinstitutionalization and the development of community-based mental health services has fortunately widened the access to psychotropic drugs and represents a step forward in mental health care. The consumption of psychotropic drugs, namely antidepressants, antipsychotics and anxiolytics, reported increasing trends in the last two decades both worldwide (OECD 2020; Bachhuber *et al.* 2016; Murphy *et al.* 2016; Xu *et al.* 2021; Hálfdánarson *et al.* 2017) and in Portugal (Caldas de Almeida *et al.* 2013), especially among women and the elderly (Semoun and Sevilla-Dedieu 2015; Carrasco-Garrido *et al.* 2016). However, thorough surveillance is important to tackle issues concerning inequalities in access, overuse of psychotropics like benzodiazepines, and inadequate active drug selection (Gardner 2014).

Portugal is a paradigmatic case of heavy use of anxiolytics since the 90s (Saúde 2019), as this class represents 2% of all drugs sold and the country holds the higher consumption rate among OECD countries. However, the prescription trend of this therapeutic group has remained

^a Instituto de Medicina Preventiva, Faculdade de Medicina da Univ. de Lisboa; Hospital CUF Descobertas; luismadeiramd@gmail.com

 $[^]b\textit{ACES Baixo Vouga, ARS Centro, Portugal; gbqueiroz@arscentro.min-saude.pt}$

^C INESC-ID and Instituto Superior Técnico, Universidade de Lisboa, Portugal; rmch@tecnico.ulisboa.pt

Corresponding author: Rui Henriques. Address: INESC-ID, R. Alves Redol 9, 1000-029 Lisboa, Portugal

stable (OECD and EU 2018). As for antidepressants, Portugal is the fifth OECD country with highest consumption rate, with past data evidencing increasing trends similar to other countries, like the UK, where it almost doubled in the last decade (Saúde 2019). Finally, antipsychotic consumption has also registered considerable upward trends, even though Portugal kept an average consumption below the OECD average (Saúde 2019). However, most data on consumption is outdated, especially concerning antipsychotics. Besides, by focusing only on consumption rates, it fails to comprehend the dynamics of access to mental healthcare, the speciality responsible for that care and medication adherence. This information is vital to health policy and planning, and can help to design more effective and tactical campaigns aiming to improve the quality of prescription, the communication between primary and hospital care, and non-pharmacological support.

Most health data in Portugal is currently fully digital and centralized in the Shared Services Ministry of Health (SPMS), comprehending data on demographics and clinical records, and an electronic prescription platform (PEM) that allows tracing of every prescription, both public and private. This represents an excellent opportunity in the European context to study nationwide pharmacoepidemiological factors and offer a systematic assessment and characterization of the prescription and consumption trends of psychiatric drugs from 2016 to 2019.

The proposed epidemiological study is the first one comprehensively traversing the Portuguese status on psychotropic drug prescription along the years preceding the COVID 19 pandemic. In addition, it further reveals sociodemographic determinants, the incidence of prescriptions per medical specialty, the associated expenditures, geographic discrepancies, and compliance rates.

2 Methods

We performed a descriptive non-comparative cohort study, with data related to all users in Portugal with registered prescriptions of any antipsychotic, antidepressant, or benzodiazepine approved for commercial usage by Infarmed (active principles listed in Appendix B1) from 1/1/2016 to 31/12/2019.

For each user (granted anonymity), we collected data on gender, age group (10-year ranges), residency, and their respective prescriptions. For each prescription, we collected the medical prescription identifier, the medical speciality of the prescriber, the week of prescription, the municipality where it took place, and a package code with information on active principle, commercial name, number of units, dosage form and pharmaceutical formulation.

All data was mapped onto a relational database where the profile of the user, geographical aspects, the description of the drugs, and the characteristics of the packages in the prescriptions were decoupled to promote time and memory efficiency associated with data exploration tasks. Data were preprocessed to correctly map equivalent coding.

The number of residents per municipality and national district for different gender and age groups were collected from the portal Instituto Nacional de Estatística (INE).

The users' municipality of residence was inferred from their primary health care centre, not from the place of prescription, which is often carried out in central hospitals.

Drug prescription is expressed in Defined Daily Dose per 1000 inhabitants-days (DID). The Defined Daily Dose (DDD) corresponds to the assumed average maintenance dose per day for a drug used for its main indication in adults. For this, we first assigned a DDD to each active ingredient in the study according to its ATC code, using the guidelines of the World Health Organization (WHO). In the case of drugs without an ACT code, a DDD value was assigned based on previous studies with the same active ingredient¹. The DDD units per package were calculated and assigned to their identifier. The complete list of packages and correspondent DDD can be consulted in Appendix B2. DID of each active ingredient was then obtained by multiplying the DDD units per package by its total prescription and divided by the target population size and period of study.

^{1.} https://www.whocc.no/atc_ddd_index/

To account for meaningful deviations, the geographic distribution of DID statistics are standardized by the age distribution of citizens along the Portuguese territory, unless stated otherwise.

The data processing, user location estimates, and subsequent analytical tasks were conducted using Python and PostgreSQL. The graphical presentation of statistics was carried out in Plotly.

3 Results

Birds-eye view of data

This study covers a total of 46,161,485 prescriptions, of which 17,529,112 correspond to antidepressants, 6,541,283 to antipsychotics, and 22,091,090 to benzodiazepines. Tables 1-4 summarize the yearly statistics of the national cohort across drug classes, gender, age, and geography. Table 1 presents the distribution of consumption rates in DIDs; Table 2 assesses the adherence rate (consumption to prescription DID ratio); Table 3 provides the number of prescribed users; and Table 4 summarizes the total expenditures.

Table 1. Summary of the psychodrug consumption status in Portugal: consumption rates across demographic variables expressed in Defined Daily Dose per 1000 inhabitants-days (DIDs).

			2016	antipsy 2017	chotics 2018	2019	2016	antidepi 2017	ressants 2018	2019	2016	benzodia 2017	azepines 2018	2019
		all	10.93	12.90	13.38	14.17	83.03	97.78	103.66	111.82	57.86	65.31	65.00	64.33
_	gender	F M	10.18 11.76	12.06 13.84	12.59 14.24	13.31 15.11	121.43 40.65	142.30 48.63	150.37 52.10	161.69 56.78	77.22 36.49	86.91 41.46	86.14 41.65	85.00 41.52
consumption rates (DIDs)	age	[18-29] [30-39] [40-49] [50-59] [60-69] [70-79] [+80]	5.02 9.37 14.65 16.68 15.08 14.53 22.25	5.89 10.49 16.94 19.69 18.06 17.41 27.88	6.23 10.26 17.10 20.26 18.93 18.62 30.35	6.75 10.52 17.84 21.45 20.24 19.80 32.86	17.24 42.02 81.68 118.94 154.83 184.41 195.68	20.25 45.94 94.18 137.33 181.15 220.94 248.02	21.88 45.91 97.93 142.78 191.92 237.61 275.85	24.76 47.46 103.97 151.99 205.38 259.98 306.71	6.20 20.91 49.08 81.79 114.65 140.91 162.92	6.80 21.86 54.10 91.79 129.98 159.64 191.37	6.68 20.59 52.97 90.83 129.26 160.08 195.63	6.69 19.56 51.80 89.13 127.30 159.77 198.28
const	region	alentejo algarve centro lisboa norte	10.83 10.08 12.10 11.54 9.92	13.18 11.54 13.96 14.02 11.58	13.82 12.40 14.50 14.58 11.89	14.63 13.62 15.26 15.29 12.73	78.33 50.54 87.59 79.77 87.42	91.22 59.59 100.60 96.10 103.27	96.81 64.21 105.89 102.28 109.64	102.85 70.13 113.70 110.61 118.78	45.26 35.11 62.56 42.86 72.01	50.06 40.42 70.01 49.11 81.30	48.80 41.25 69.76 48.66 81.22	47.92 42.33 68.56 48.42 80.49

Table 2. Therapeutic adherence in Portugal: consumption to prescription DIDs ratio per demographic group.

			2016	antips 2017	ychotics 2018	2019	2016	antidep 2017	ressants 2018	2019	2016	benzodi 2017	azepine: 2018	s 2019
	all		0.88	0.82	0.81	0.81	0.87	0.79	0.79	0.79	0.97	0.96	0.96	0.96
	gender	F M	0.87	0.80 0.83	0.80 0.82	0.80 0.82	0.86	0.79 0.80	0.79 0.79	0.79 0.79	0.97 0.97	0.96 0.97	0.96 0.96	0.96 0.96
adherence ratio	age	[18-29] [30-39] [40-49] [50-59] [60-69] [70-79] [+80]	0.86 0.87 0.87 0.87 0.88 0.88 0.90	0.80 0.81 0.82 0.81 0.82 0.82 0.83	0.79 0.80 0.81 0.81 0.81 0.82 0.83	0.78 0.80 0.80 0.80 0.81 0.81 0.82	0.86 0.86 0.86 0.85 0.87 0.87 0.89	0.77 0.77 0.78 0.78 0.80 0.81 0.82	0.76 0.77 0.78 0.78 0.80 0.80 0.81	0.76 0.77 0.78 0.78 0.80 0.80 0.81	0.96 0.97 0.97 0.97 0.97 0.98 0.98	0.95 0.95 0.95 0.96 0.96 0.97	0.95 0.95 0.95 0.96 0.96 0.97 0.96	0.94 0.95 0.95 0.95 0.96 0.97 0.96
	region	alentejo algarve centro lisboa norte	0.85 0.87 0.87 0.87 0.89	0.79 0.78 0.82 0.80 0.84	0.77 0.78 0.82 0.79 0.84	0.78 0.77 0.81 0.79 0.83	0.84 0.85 0.86 0.86 0.88	0.78 0.74 0.79 0.78 0.81	0.77 0.75 0.80 0.77 0.81	0.77 0.75 0.80 0.78 0.81	0.96 0.97 0.97 0.97 0.97	0.95 0.95 0.96 0.96 0.97	0.95 0.95 0.96 0.96 0.97	0.95 0.95 0.96 0.95 0.96

Table 3. Number of prescribed individuals with psychotropic drugs per demographic group.

			2016	antipsy 2017	chotics 2018	2019	2016	antidepr 2017	essants 2018	2019	2016	benzodia 2017	zepines 2018	2019
	all		388,305	417,156	432,809	446,390	1221,550	1305,811	1358,035	1421,671	1506,424	1561,381	1537,151	1523,839
S	gender	F M	238,947 149,358	256,735 160,421	266,587 166,222	274,631 171,759	911,818 309,732	969,431 336,380	1004,136 353,899	1046,860 374,811	1041,085 465,339	1073,270 488,111	1053,174 483,977	1041,837 482,002
number of use	age	[18-29] [30-39] [40-49] [50-59] [60-69] [70-79] 80+	19,853 32,060 54,747 64,775 63,728 65,931 87,211	21,398 32,222 57,949 69,473 68,926 70,339 96,849	22,186 31,393 58,791 71,299 71,336 73,267 104,537	23,546 31,175 59,257 72,917 73,042 75,663 110,790	54,576 107,118 191,059 237,559 246,970 220,607 163,661	59,380 107,940 202,614 251,211 263,974 237,516 183,176	61,886 106,091 207,224 258,342 275,104 251,242 198,146	67,373 107,395 214,524 267,456 286,604 265,031 213,288	54,585 110,312 205,365 277,900 321,406 302,742 234,114	57,737 110,130 213,349 287,245 333,187 311,900 247,833	58,612 104,147 208,174 279,901 326,665 309,532 250,120	59,670 101,252 205,690 275,419 321,077 308,738 251,993

Table 4. Total expenditure (kEur) and governmental participation (kEur) with psychotropic drugs in Portugal.

			2016	antipsy		2010	2016	antidep		2010		benzodia	•	2010
			2016	2017	2018	2019	2016	2017	2018	2019	2016	2017	2018	2019
	all		54,925	59,728	60,414	63,290	23,908	28,254	29,810	32,355	14,671	16,040	15,771	15,655
volume of sales (1000Eur)	region	alentejo	4,465	4,915	4,989	5,218	1,983	2,325	2,461	2,658	1,097	1,180	1,140	1,112
S Sa		algarve	2,089	2,305	2,597	2,850	710	818	863	946	463	513	518	530
?७ ≘		centro	14,330	15,437	15,883	16,691	6,345	7,402	7,730	8,295	3,848	4,226	4,160	4,124
_		lisboa	16,985	19,098	19,564	20,211	6,046	7,281	7,709	8,387	3,172	3,509	3,429	3,396
		norte	17,056	17,974	17,381	18,320	8,825	10,428	11,047	12,069	6,090	6,612	6,525	6,492
E	all		62,828	71,128	72,268	74,845	66,464	77,535	81,878	88,827	32,878	36,868	36,859	36,873
public copay 1000Eur)	region	alentejo	5,081	5,850	5,949	6,136	5,181	5,988	6,325	6,782	2,377	2,618	2,573	2,544
3 8		algarve	2,390	2,728	3,077	3,330	2,084	2,393	2,525	2,741	1,092	1,244	1,281	1,321
- 1		centro	16,404	18,377	18,915	19,631	17,164	19,477	20,343	21,859	8,447	9,386	9,409	9,371
		lisboa	19,496	22,658	23,331	23,864	17,870	21,301	22,475	24,337	7,526	8,587	8,548	8,573
		norte	19,457	21,515	20,996	21,884	24,165	28,376	30,211	33,108	13,436	15,034	15,048	15,065

Prescription and consumption profile by class of psychotropic drugs (2016–2019)

Tables 1–2 and supplementary Figure A1 disclose the consumption rates (DIDs), number of users, and expenditure volumes during the period of analysis for the three classes of psychotropic drugs. Significant growth is observed in the number of users with prescribed antidepressants and antipsychotics (Figure A1a), representing a 20% increase between 2016 and 2019 in both classes – approximately 250,000 new users with prescribed antidepressants and 100,000 new users with prescribed antipsychotics. The number of users with prescribed benzodiazepines is considerably high, 1.5% (>15% of the Portuguese population) and yet does not seem to be in an increasing trend.

The progression of the consumption rates (DIDs) per active drug is provided in Figure 1. Figure A2 in appendix complementarily depicts the number of prescribed users per drug. When considering antidepressant prescriptions (Figures 1a and A2a), we find an increasing trend for selective serotonin reuptake inhibitors where sertraline and escitalopram are among the top 3 most prescribed AD as well as alpha-2 antagonists, particularly trazodone and mirtazapine. The prescription of SNRIs, such as venlafaxine and duloxetine also shows an upward trend in contrast to tricyclic antidepressants showing a clear downward trend. Except for amitriptyline, the prescription of dosulepin, maprotiline, trimipramine, nortriptyline, imipramine and pirlindole seems to suggest discontinuation of their use.

Considering antipsychotics (Figures 1b and A2b), there is a clear prescription tendency towards atypical antipsychotics, with a particular incidence on quetiapine (with an increase of approximately 20,000 users per year), risperidone and olanzapine. Among the typical antipsychotics, amisulpride stands out with a stable prescription rate throughout the study period. The consumption rates of zuclopenthixol, ziprasidone, pimozide, flupentixol and fluphenazine are increasingly residual.

The prescription of benzodiazepines (Figures 1c and A2c) appeared stable in the years we analyzed with a clear preference for the prescription of alprazolam, diazepam, lorazepam and bromazepam, and an increasing trend in the prescription of mexazolam.

Demographic profiles

The gender and age distribution of consumption rates (Table 1), number of prescribed users (Table 3), and expenditures is visually depicted in the supplementary Figures A3 to A8. We observe a higher incidence of psychotropic drug consumption and prescription in women in all our sub-samples, and significantly higher consumption rates (DID) in the age groups above 40 years (*p*-value<1E-3, quarter estimates). Those at a younger age seem to represent a considerably smaller share of pros and yet appear to be growing expressively (Tables 1 and 3; 18-29 years). Finally, we observed that the volume of expenditure is on par with the incidence of prescriptions in the female population. However, in the male population younger users seem to represent a larger spending per volume of prescriptions. The proportion of antidepressants, antipsychotics and benzodiazepines does not




Figure 1. Defined daily dose per 1000 inhabitants-days (DID) per psychotropic drug between 2016 and 2019.

differ significantly by age group. However, there is a predominance of antidepressant use over benzodiazepines in the younger age groups.

Considering the gender distribution per psychotropic drug (Figures A7 and A8), we observe that most drugs do not generally show a significant deviation from gender distribution expectations (p-value<1E-3), with few exceptions, including tiapride which is more frequent in men.

Geographical Distribution

The geographical incidence of consumption rates, prescribed users, and total-and-relative expenditures by group of psychotropic drugs is visually drawn in supplementary Figures A9 and A10. The allocation of users across geographies was inferred from their primary health care centre and not from the place of prescription (as it is often carried out in large centres). The analysis of the geographical distribution of consumption rates (Table 1, Figure A9), standardized by the age distribution of citizens per region, reveals some divergences - the Algarve being the region with the lowest consumption of antidepressants and anxiolytics, and the North of Portugal having the lowest consumption of antipsychotics but the highest consumption of anxiolytics. Regions with incidence of prescription per resident above the average include Coimbra, Évora and Portalegre while Faro and Setubal have incidences below the average. The analysis of the variability observed between quarters confirms the statistical significance of the differences reported (t-test, $\alpha = 1E$ -3, quarter estimates).

Additionally, the analysis of total expenses and co-payments per district (Figure A10) shows considerable agreement with the volume of users (Figure A9). The Centre region stands out as the one that produces the highest expenditure per user, both in total volume and in the volume of state co-payments. In Porto and Guarda regions, despite the number of users being in line with the average, the volume of reimbursements per resident is below average, due to a lower average number of prescriptions per user.

Figure A11 breaks down the expenditure analysis by district to acquire a finer spatial granularity with the aim of identifying areas with deviating prescription profiles in the Portuguese territory.

Medical specialty of the Prescriber

An initial view of the consumption and prescription rates, the number of prescribed users, and total volume of prescriptions by medical specialty and class of psychotropic drugs is presented in Figures 2 and A12. For this analysis, all prescriptions made between 2018 and 2019 were considered. First, we observe that over two-thirds of benzodiazepine prescriptions are carried out in General Family Practice, with the sum of all prescribed users by the remaining medical specialties responsible for one third, including psychiatry (11% of prescriptions) and internal medicine (5% of prescriptions). Secondly, and analogously, there is similar representativeness in the prescription of antidepressants, with General Family Practice comprising more than 60% of prescriptions. In this class of psychotropic drugs, psychiatry and neurology specialties have a higher share of prescriptions, representing approximately 20% and 6% of the total volume of prescriptions. Third, General Family Practice is the specialty that most prescribed antipsychotics (47% of prescriptions), followed by psychiatry (34%), which together are responsible for prescribing approximately 80% of antipsychotic prescriptions.

Figure A13 place the focus on the proportion of psychotropic drug classes by medical specialty. Most medical specialties prescribe more benzodiazepines and a reduced proportion of antipsychotics (less than 10% of total prescriptions in more than 80% of the specialties). Alongside this observation, there are significant variations in the proportion of prescriptions for each class of psychotropic drugs between medical specialties.

Looking in detail at the drugs by group in Figure 3, we can observe that the proportion of the different antidepressants does not differ significantly from specialty to specialty. Nevertheless, we observe that surgery, neurology, orthopaedics and rheumatology prescribe significantly more amitriptyline and duloxetine than the remaining specialties. In turn, psychiatry prescribes some active substances with low prescription in the other specialties, including citalopram, clomipramine, fluvoxamine and vortioxetine.

In the context of antipsychotic prescriptions, there is also a balanced drug distribution per specialty, with a clear cross-sectional preference for quetiapine. Medical oncology seems to make more relative use of haloperidol than other specialties, which seems to be motivated by its role in reducing nausea and vomiting as a complement to its antipsychotic functions. Similarly to antidepressant prescription, we observed that psychiatry prescribes moderately some antipsychotics, such as aripiprazole and paliperidone, with residual representation in the other specialties.




Figure 2. Prescribing medical specialty, 2018–2019.




Figure 3. Distribution of psychotropic drugs (DIDs) prescribed per medical specialty, 2018–2019.

Finally, in terms of benzodiazepines, we also observed a non-deviating distribution of drugs by specialty. specialties with low prescriptions of benzodiazepines tend to prefer diazepam, while specialties with more active prescription profiles tend to prefer alprazolam. In psychiatry and oncology, the consistent preference for lorazepam also stands out.

4 Discussion

Our data suggest an overall increase in the prescription rates, volume of expenditure, number of prescriptions, and cases prescribed over the years — the Portuguese trend is similar to worlwide trends (OECD 2020; Bachhuber *et al.* 2016; Murphy *et al.* 2016; Xu *et al.* 2021; Hálfdánarson *et al.* 2017). This increase was greater between 2016 and 2017, probably reflecting a change in policy regarding the mandatory use of PEM, thus increasing the prescription registry. Among the three drug classes, the antidepressants were the ones that suffered the largest increase during this period, with more 45,13 DID than the ones prescribed in 2016, corresponding to a 47% increase. The last studies on the matter in Portugal reported a 20% increase per year in the antidepressant consumption rates between 2000 and 2012 (Caldas de Almeida *et al.* 2013). This new data shows that this trend seems to be slowing down, yet solidly positive. It is also important to notice that, especially within this class, this trend may have accelerated after 2019 considering the impacts of the COVID-19 pandemic.

When considering the OCED report on antidepressant consumption, our results are in line with the presented estimates up to 2017 (OECD and EU 2018), confirming that Portugal is significantly above the OECD average for antidepressant use (63.3 DID). The continuous increasing trend may result from an improved recognition of mental disorders and accessibility to treatment, including better clinical guidelines. However, it is also likely to be associated with increased societal stressors; the worsening of medical intervention, namely shorter consultation length and lesser frequency; as well as the loss of psychosocial interventions (Tobin, Bury, and Cullen 2020; Johnson et al. 2017).

SSRIs stand out as the most prescribed antidepressants which are along with the guidelines for depressive and anxiety disorders and evidence from other countries (Bogowicz *et al.* 2021; Dai Cao *et al.* 2021; Livingston 2020). This type of antidepressant, particularly sertraline, is probably preferred by physicians due to its well-documented great combination of efficacy and acceptability (Cipriani 2020). An atypical antidepressant, trazodone, is the fifth most prescribed drug in the country, a fact probably justified by its use as an add-on during adjustment reactions and depressive episodes in users with insomnia. In fact, data from the United States of America show that most trazodone prescriptions are explained by its off-label use for the treatment of primary or secondary insomnia (Stahl 2009). In another stance, tricyclic antidepressants (TCA) seem to have become discontinued, perhaps due to their low safety and tolerability. However, as observed in similar studies (Lockhart and Guthrie 2011; Saragoussi *et al.* 2012), amitriptyline stands out in this scenario, probably, again, derived from its non-FDA approved uses for symptoms and disorders such as insomnia, chronic pain or bladder pain syndrome (Sultana *et al.* 2014; Verhaak, Beurs, and Spreeuwenberg 2019).

When looking at the use of antipsychotics, Portugal also registers a clear upward trend of its prescription, with a 41% increase in this period, especially among atypical antipsychotics, with quetiapine standing out as the most prescribed antipsychotic in Portugal. This can be partly explained by its off-label use for non-approved FDA indications such as anger management, dementia and insomnia (Office of Public Affairs 2010). Despite the risk of metabolic syndrome associated with their use, risperidone and olanzapine are still prescribed to a greater extent than other antipsychotics, possibly due to their key sedative properties and approval in non-psychotic mood disorders. Amisulpride prescription also stands out perhaps due to its use in depressive symptoms in those with assorted mental symptoms (e.g. conversion/somatic), as an add-on for bipolar type-1 disorders (Zangani et al. 2021; Carta et al. 2006), rather than its sole use as an antipsychotic agent (Nuss, Hummer, and Tessier 2007). As observed with tricyclic antidepressants, several first-generation antipsychotics are no longer part of Portugal prescription choices, probably exposing their side effect profile as D2 antagonists (extrapyramidal effects) or low antipsychotic effect (Buhagiar, Ghafouri, and Dey 2020; Marston et al. 2014; Morrens et al. 2015; Prah et al. 2012; Shah et al. 2011). In the transition to second-generation antipsychotics, ziprasidone seems an exception, with a reduction in its prescription, perhaps for alternate drugs choice with better safety and tolerability profile

(e.g. vs aripiprazole) and efficacy (e.g. vs olanzapine and risperidone) (Gardner *et al.* 2013). The growing use of antipsychotics could also be explained their increasing use in Bipolar Disorder (Hayes *et al.* 2011), and the growing familiarity of its prescription among GPs, able to manage them better than in the past and are less afraid of using them (Buhagiar, Ghafouri, and Dey 2020; Livingston 2020; Morrens *et al.* 2015).

The prescription of benzodiazepines, desspite the sudden increase in the first year of the study, seem to be stable from 2017 to 2019. This might refer not only to a growing consciousness of potential hazards associated with its use but to the crescent shift to SSRIs (Rosman, Le Vaillant, and Pelletier-Fleury 2011; Šubelj, Vidmar, and Švab 2012). However, it is worth noticing that this overall trend is supported by the decrease in prescriptions among younger adults (18-69 years), while an increase for users above 70 years old is still evident. This is of particular concern as benzodiazepines are considered a potentially inappropriate medication (PIM) in this population and their prescription should be avoided (American Geriatrics Society et al. 2015; O'Mahony et al. 2018). With respect to the general choice of benzodiazepines, our results go along with previous evidence where alprazolam, diazepam and lorazepam are the most commonly prescribed anxiolytic drugs (Rosman, Le Vaillant, and Pelletier-Fleury 2011; Šubelj, Vidmar, and Švab 2012). Indeed, alprazolam was the most prescribed in our sample, likewise prescription practices of most countries in the world (Ait-Daoud et al. 2018). While short half-life benzodiazepines such as alprazolam may represent fewer hazards (Hanlon et al. 2002) they are frequently associated with dependence (Cuevas, Sanz, and Fuente 2003). Alprazolam use is seconded by diazepam, a long-acting benzodiazepine with more than 50 years of history, while lorazepam takes up the 3rd place in the prescription profile which is along with its extensive and safe use in situations where there is liver disease/damage (Ghiasi, Bhansali, and Marwaha 2021).

Considering the demographic correlates, although the use of psychotropics at younger groups represent a smaller share, they seem to grow expressively from 2016 to 2019, a trend in line with what's happening other countries (Jack et al. 2020). This can either moved by societal stressors, earlier diagnosis, and/or failure to provide other forms of early intervention (e.g. psychotherapy). This increase is in conformity with previous evidence that considers aggravated societal factors (employment insecurity, low income, reduced social benefits and recession) impacting the mental health in youth (Silva et al. 2020). The prescription of psychotropics in subjects over 50 years constitutes more than 50% of the Portuguese total share and, while this can be driven by the ageing of the Portuguese population (Ćurković et al. 2016), it can be aggravated by the cumulative effect of the use of psychotropic drugs in adaptive reactions which are kept beyond their actual needs. In all three drug classes, the consumption rates increases with age. With antidepressants and benzodiazepines, we observe a linear progression, with an increase of 49,5 DID of antidepressants and 28,4 DID of benzodiazepines per age group. In the case of antipsychotics use, there is a slow increase from 18 to 49 years which becomes stable until reaching the group above 80 years old, where it suddenly increases by 63,8%, a fact that could be explained by their use in dementia profiles, amongst other conditions (IHME 2022, 2019). While the higher incidence of antipsychotics in the >80 years old group might correspond to actual needs for behaviour control and other neuropsychiatric symptoms (Liperoti, Pedone, and Corsonello 2008), there is evidence alerting to the fact that, in some contexts, only 10% of psychotropic drugs in the elderly are correctly prescribed (Spek et al. 2016). Studies and policies to treat mental health disorders in elderly ages are thus fundamental to assess the current status and the role of non-pharmacological intervention on issues such as loneliness that could reduce the use of psychotropic drugs. Considering benzodiazepines, an increase has been observed for young populations in many countries, frequently associated with long-term use patterns against international and national guidelines (Sidorchuk et al. 2018). In contrast, in the Portuguese case, a higher proportion of this age group uses antidepressants. While we can hypothesize that the clinicians awareness to paradoxical effects of benzodiazepines

in adolescents (Mancuso, Tanzi, and Gabay 2004) or cautions related with the risk of addiction support this observation, we further hypothesize that these results are complementarily driven by the increasing evidence given to the selection of antidepressants as the long term psychotropic choice of treatment for anxiety (Gomez, Barthel, and Hofmann 2018) and depressive disorders (Kendrick, Taylor, and Johnson 2019).

Women represent the group with the highest consumption rates (DIDs) in general, approximately three times more antidepressants, as well as two times more benzodiazepines, than men. The observed gender distribution of psychotropic drug use is supported by previous worldwide (Boyd *et al.* 2015) and Portuguese studies (Silva *et al.* 2020). Discussion on this topic includes the possibility that men could be under-treated and women over-treated with antidepressants (Sundbom *et al.* 2017). While some consider adaptive reactions to be more common in women, the most frequently considered reason for this clear discrepancy is that internalized stigma for help-seeking might hinder the medicalization of suffering in males. Only in the antipsychotic prescriptions do men register higher values with a 14% higher consumption rate. Tiapride use in Alcohol Use Disorders, more prevalent in men (Glantz *et al.* 2020), might explain this fact.

The geographical distribution of prescriptions (adjusted for age) also reveal important discrepancies. The North region records the highest prescription rates of antidepressants and benzodiazepines, but the lowest for antipsychotics. Our results are against recent evidence suggesting heavy use of antipsychotics in rural areas in the north of Portugal (Ramos *et al.* 2021). The Algarve region, on the contrary, always assumes low rates in comparison to other regions. This may reflect a chronic lack of access to primary care in this region, with some users being followed up in central hospitals outside Algarve, as well as an increased dependency of the private sector. As the region with most relative coastal area, the exposure to blue spaces may also play a role in these results. Several previous studies suggest that socioeconomic status (inc. health insurance) can underlie geographical differences in prescription patterns (Dennis *et al.* 2020). Future studies are necessary to outline the determinants for higher prescription in each region and support the implementation of subsequent mitigation strategies.

As seen in Figure 2 on the medical speciality responsible for the prescription, General Practitioners (GPs) preside over all other specialties in all three-drug classes, while psychiatry and neurological specialty are together responsible for only 21% of overall prescriptions. In Portugal, primary care services are a strong component of the National Health Service, with GPs being responsible for the management of non-complex affective disorders, as well as the follow-up of chronic and stable psychiatric disorders. This is along with evidence in other countries where GPs are responsible for most drug prescriptions (Mercier et al. 2015; Johnson et al. 2017; Svensson, Hedenrud, and Wallerstedt 2019). This observation outlines the need for intervention in the training and clinical support about treatment of mental health and psychotropic drugs among GPs, and the introduction of good practice goals in the annual action plans of the primary care units. Our results for antidepressants show a higher use of citalogram, fluoxetine and sertraline as observed in previous studies (Johnson et al. 2017) and there seems to be evidence of off-label prescription (Rubio-Valera et al. 2012). GPs seldomly use recent psychotropics (Svensson, Hedenrud, and Wallerstedt 2019) or else rely on direct marketing strategies to identify new treatments (Mercier et al. 2011) which are adopted under the premise that these new drugs are more effective (Svensson, Hedenrud, and Wallerstedt 2019). Although the use of benzodiazepines and antidepressants is not restricted to the treatment of mental disorders, our figures also raise important considerations regarding the monitoring of users prescribed for mental disorders by other medical specialities, including psychiatry, neurology, and surgery. Short and long term treatment with benzodiazepines might risk being outdated or beyond rationale from the National Institute for Health and Care Excellence (NICE) if not validated by proper specialities (e.g. neurology and psychiatry). Liaison psychiatry should play an important role here. We further observed that surgery, neurology, orthopaedics and

rheumatology prescribe significantly more amitriptyline and duloxetine than the remaining specialities, an observation that is associated with the role of these drugs in neuropathic pain control and enuresis (Reddy and Patt 1994). The case of antipsychotics use, which FDA and EMEA approved for symptomatic treatment of psychoses and affective disorders, the extensive prescription rate by GPs could constitute either an off-label use for insomnia or behavioural symptoms, as well as the result of a long term treatment of stabilized effective schizophrenia spectrum disorders under the care of a GP.

Limitations

First, our study excludes non-benzodiazepine anxiolytic drugs such as zolpidem, limiting our results to the class of benzodiazepines, a care to be undertaken when establishing comparisons against DID references in other countries and historical estimates in Portugal. Although DDD and DID are still considered to be the reference indicators for pharmacoepidemiology studies alike, they can fail to capture the micro tendencies of each prescription and the diagnosis it serves. Due to multi-level privacy concerns, several clinical inputs (e.g. diagnosis information) could not be collect at a nationwide level, which would be pivotal to understand the psychiatric dynamics that go along with the depicted trends, thus preventing us to inquiry whether the changes in prescription and consumption are related with the increasing prevalence of mental illness. Despite our care in identifying geographical residence of individuals by primary healthcare service (the selected coarse-grained territorial division already mitigates this bias), several geographic discrepancies may refer to centralized mental healthcare treatment in Portugal. In addition, we were not provided with complete prescription registry from the autonomous regions of Azores and Madeira due to the non-mandatory use of electronic registry in these regions throughout the period of the cohort study. The inclusion of these regions is expected in the future for an all-encompassing analysis of the country. Finally, there is a remnant use of paper prescriptions up to 2017, nevertheless credited by the Health Ministry as being largely residual and thus not determinant for analysis or discussion.

5 Conclusions

This study is the first comprehensively examining and discussing the prescription patterns of psychotropic drugs in Portugal across years 2016-2019. Several of the acquired results are in line with the existing body of research in other countries – an increase in consumption rates and volume of expenditure, as well as a consolidation trend towards the prescription of specific groups of psychotropic drugs. In particular, we observed an increase in the consumption (>30%) and expenditure (37M Eur) of antidepressants and antipsychotics between 2016 and 2019, and a stabilization on the use of benzodiazepines with an overall consumption by >15% of the Portuguese population. With few exceptions, tricyclic antidepressants and typical antipsychotics seem to be under discontinuation suggesting prescribers are favouring SSRIs and atypical drugs. The use of psychotropic drugs seems to be higher in those of older age and in women, and disparate among different Portuguese regions (after correction for age). Sociodemographic, geographical and cost correlates are explored, unraveling relevant drivers to assess the status of psychotropic drug prescription. The analysis of the responsible medical specialities reveals that General Medicine is responsible for approximately 64% of prescriptions, and is arguably less assorted in the choices when considering the changing in the preferred psychotropic drugs by psychiatry and neurology.

Unique aspects to the Portuguese case are also noted and discussed, including the ageing of the Portuguese population, the follow up of mental disorders in GP, and the economic recession.

Our findings ultimately constitute opportunities for public health initiatives, the design of new practice recommendations for psychotropic drug prescription, medical training programs, the strenghtening of protocols between psychiatrists and GPs, as well as psychosocial interventions.

We aim to further assess the patterns of psychotropic drug prescription in Portugal by continuing with the collection and processing of PEM data for the subsequent years, estimating the potential impact yield throughout and after the COVID 19 pandemic in the consumption status. In addition, we expect to source complementary clinical data (e.g., diagnosis and interventions) that can be crisscrossed with the available data to understand the underlying rationale for the different patterns of prescription, and set tailor made protocols for deprescribing strategies. As our study further suggests that several prescription patterns, either for their possible long-term or off-label use, should be closely monitored, we further aim to analyze the prescription registries to study malprescription patterns, including problems of poliprescription.

Acknowledgments

The authors thank Serviços Partilhados do Ministério da Saúde (SPMS) for the valuable data provision and support. This research work was further supported by national funds through Fundação para a Ciência e Tecnologia (FCT) under INESC-ID pluriannual (UIDB/50021/2020).

Competing interests

The authors declare that they have no known competing interests.

Appendix

A1 Complementary results




Figure A1. Yearly progression of prescription indicators per psychopharmaceutical drug class between 2016 and 2019.

Table A1. Summary of the psychotropic drug prescription status in Portugal: prescription rates across demographic variables expressed in Defined Daily Dose per 1000 inhabitants-days (DIDs).

			2016		chotics	2010		antidep		2010		benzodia	-	
			2016	2017	2018	2019	2016	2017	2018	2019	2016	2017	2018	2019
	all		12.48	15.82	16.51	17.56	95.97	123.04	130.76	141.09	59.53	67.91	67.62	67.04
(DIDs)	gender	F M	11.72 13.31	15.00 16.72	15.75 17.35	16.70 18.51	140.53 46.77	179.20 61.04	189.68 65.72	203.91 71.74	79.55 37.44	90.54 42.94	89.77 43.18	88.72 43.10
prescription rates (DI	age	[18-29] [30-39] [40-49] [50-59] [60-69] [70-79] [+80]	5.83 10.76 16.78 19.18 17.22 16.45 24.72	7.41 12.95 20.76 24.23 22.08 21.23 33.47	7.93 12.78 21.17 24.98 23.31 22.84 36.72	8.64 13.13 22.19 26.65 25.00 24.32 39.84	20.15 49.07 95.37 139.25 178.54 211.30 221.07	26.41 59.43 120.43 175.51 226.32 274.11 303.36	28.71 59.72 125.75 182.68 240.07 295.33 339.29	32.45 61.86 133.44 194.32 257.09 323.00 378.73	6.44 21.66 50.77 84.53 117.79 144.39 166.80	7.18 23.01 56.73 95.98 134.76 164.93 198.09	7.06 21.72 55.60 94.97 134.06 165.40 202.74	7.08 20.65 54.47 93.33 132.16 165.34 206.02
. d	region	alentejo algarve centro lisboa norte	12.71 11.61 13.85 13.32 11.10	16.65 14.72 17.10 17.52 13.77	17.93 15.92 17.75 18.37 14.23	18.89 17.61 18.77 19.35 15.30	93.38 59.59 102.25 92.29 99.53	117.53 80.10 126.78 123.25 126.78	125.81 86.14 133.28 132.01 134.73	133.91 94.09 142.47 142.69 146.51	47.02 36.32 64.46 44.15 73.86	52.64 42.57 72.81 51.35 84.11	51.38 43.37 72.61 50.87 84.09	50.60 44.57 71.41 50.72 83.46

Table A2. Volume and share of prescriptions per medical specialty and psychotropic drug class (2018–2019).

speciality	all volume share		antipsychotics volume share		antidepressants volume share		benzodiazepine volume share	
cardiology	231977	1.0%	11848	0.4%	69892	0.8%	149694	1.4%
general and family medicine	14089362	63.2%	1479899	47.4%	5083039	60.2%	7483668	70.1%
internal medicine	998272	4.5%	168474	5.4%	350966	4.2%	474543	4.5%
medical oncology	90876	0.4%	7472	0.2%	31451	0.4%	51744	0.5%
nephrology	63683	0.3%	5520	0.2%	20006	0.2%	38085	0.4%
neurology	832563	3.7%	160326	5.1%	469398	5.6%	202146	1.9%
non-specialists	168933	0.8%	25117	0.8%	56172	0.7%	86677	0.8%
occupational medicine	114671	0.5%	11885	0.4%	40304	0.5%	62053	0.6%
orthopedics/rheumatology	151611	0.7%	6610	0.2%	59932	0.7%	84736	0.8%
pneumology	95056	0.4%	9254	0.3%	32411	0.4%	53154	0.5%
psychiatry	3966556	17.8%	1055735	33.8%	1719096	20.4%	1188595	11.1%
surgery	211929	1.0%	20261	0.6%	81027	1.0%	109120	1.0%
other specialties	856131	3.8%	86177	2.8%	282776	3.4%	471762	4.4%
non specified	430540	1.9%	71625	2.3%	140771	1.7%	215403	2.0%




Figure A2. Number of prescribed citizens per psychotropic drug between 2016 and 2019.




Figure A3. Distribution of psychotropic drug prescription volume across gender and age.




Figure A4. Distribution of consumption rates (DIDs) per drug class across gender and age.




Figure A5. Distribution of the number of prescribed citizens per drug class across gender and age.




Figure A6. Distribution of psychotropic drugs per age, 2018–2019.




Figure A7. Consumption rate in DIDs per drug and gender, 2018–2019.




Figure A8. Number of prescribed individuals per drug gender, 2018–2019.




Figure A9. Drug prescription profile per geography after standardization for age groups against census data, 2018–2019.




Figure A10. Annual expenditure per geography, 2018–2019.




Figure A11. Annual expenditure per district, 2018–2019.




Figure A12. Prescribing medical specialty, 2018–2019.



Figure A13. Distribution of the prescription volume for each class of psychotropic drugs per medical specialty, 2018–2019.




Figure A14. Distribution of prescribed users per psychotropic drug and medical specialty, 2018–2019.

B1 Psychotropic drugs

antidepressants

- selective serotonin reuptake inhibitors, including Citalopram, Escitalopram, Fluoxetina, Paroxetina, Sertralina, Fluoxamina and Vortioxetina;
- selective serotonin and norepinephrine reuptake inhibitors, inc. Milnaciprano, Venlafaxina, Duloxetina;
- tricyclic antidepressants, including Amitriptilina, Imipramina, Maprotilina, Nortriptilina, Pirlindol, Trimipramina, Clomipramina, Dosulepina;
- alpha-2 antagonists, including Mianserina, Mirtazapina and Trazodona; and
- others not directly falling into one of the above classes, including Moclobemida and Reboxetina.

antipsychotics

- atypical, including Amissulprida, Aripiprazol, Melperona, Olanzapina, Paliperidona, Quetiapina, Risperidona, Sulpirida, Tiaprida, Ziprasidona, Zotepina, and Zuclopentixol; and
- *typical*, including Ciamemazina, Cloropromazina, Flufenazina, Flupentixol, Haloperidol, Levomepromazina, and Pimozida.
- **benzodiazepines**: Alprazolam, Bromazepam, Brotizolam, Cetazolam, Clobazam, Dipotassium chlorazepate, Chlorodiazepoxide (with and without clidinium bromide), Cloxazolam, Diazepam, Estazolam, Flurazepam, Loprazolam, Lorazepam, Mexazolam, Midazolam, Oxazepam, Prazepam, Temazepam e Triazolam.

B2 Dosages

Table B1. Full list of drug boxes and their corresponding ATC code, dosage, and total DDDs.

ass	active drug	mode	box	dosage per unit	total dosage (g)	ATC code	DDD	DDDs p packas
tidepressants	Amitriptilina Amitriptilina	coated tablet coated tablet	blister 60 unit(s) blister 60 unit(s)	10 mg 25 mg	0.6 1.5 4.5	N06AA09 N06AA09	75 mg 75 mg	8 20
	Amitriptilina Amitriptilina	coated tablet coated tablet	blister 60 unit(s) blister 10 unit(s)	75 mg 10 mg	4.5 0.1	N06AA09 N06AA09	75 mg 75 mg	60 1.33
	Amitriptilina	coated tablet film coated tablet	blister 20 unit(s)	10 mg	0.2	N06AA09 N06AB04	75 mg	2.66
	Citalopram Citalopram	film coated tablet	blister 56 unit(s) blister 60 unit(s)	20 mg 20 mg	1.12 1.2	N06AB04	20 mg 20 mg	56 60
	Citalopram Citalopram	film coated tablet film coated tablet	blister 56 unit(s) blister 30 unit(s)	10 mg 40 mg	0.56 1.2	N06AB04 N06AB04	20 mg 20 mg	28 60
	Citalopram Citalopram	film coated tablet film coated tablet	blister 60 unit(s) blister 28 unit(s)	10 mg 40 mg	0.6 1.12	N06AB04 N06AB04	20 mg 20 mg	60 30 56 7 5 14 15 45 6
	Citalopram Citalopram	film coated tablet film coated tablet	blister 14 unit(s) blister 10 unit(s)	10 mg 10 mg	0.14 0.1	N06AB04 N06AB04	20 mg 20 mg	7
	Citalopram	film coated tablet	blister 14 unit(s)	20 mg	0.28	N06AB04	20 mg	14
	Clomipramina Clomipramina	coated tablet prolonged release tablet	blister 60 unit(s) blister 60 unit(s)	25 mg 75 mg	1.5 4.5	N06AA04 N06AA04	100 mg 100 mg	15 45
	Clomipramina Clomipramina	coated tablet injectable solution	blister 60 unit(s) ampoule 5 unit(s) 2 ml	10 mg 25 mg/2 ml	0.6 0.125	N06AA04 N06AA04	100 mg	6 1.25
	Clomipramina Dosulepina	coated tablet coated tablet	blister 10 unit(s) blister 60 unit(s)	10 mg 75 mg	0.1 4.5	N06AA04 N06AA16	100 mg 150 mg	1 30
	Dosulepina	coated tablet	blister 20 unit(s)	75 mg	1.5	N06AA16	150 mg	10
	Duloxetina Duloxetina	gastro-resistant capsule gastro-resistant capsule	blister 28 unit(s) blister 28 unit(s)	60 mg 30 mg	1.68 0.84	N06AX21 N06AX21	60 mg 60 mg	28 14
	Duloxetina Escitalopram	gastro-resistant capsule film coated tablet	blister 7 unit(s) blister 56 unit(s)	30 mg 20 mg	0.21 1.12	N06AX21 N06AB10	60 mg 10 mg	3.5 112
	Escitalopram	film coated tablet	blister 56 unit(s)	10 mg	0.56	N06AB10	10 mg	56 60
	Escitalopram Escitalopram	film coated tablet orodispersible tablet	blister 60 unit(s) blister 56 unit(s)	10 mg 10 mg	0.6 0.56	N06AB10 N06AB10	10 mg 10 mg	56
	Escitalopram Escitalopram	orodispersible tablet film coated tablet	blister 56 unit(s) blister 14 unit(s)	20 mg 10 mg	1.12 0.14	N06AB10 N06AB10	10 mg 10 mg	112 14
	Escitalopram Escitalopram	oral drops - solution film coated tablet	dropper bottle 1x 15 ml blister 20 unit(s)	10 mg 20 mg/ml 10 mg	0.3 0.2	N06AB10 N06AB10	10 mg 10 mg	30 20
	Escitalopram	film coated tablet	blister 60 unit(s)	20 mg	1.2	N06AB10	10 mg	120
	Fluoxetina Fluoxetina	capsule capsule	blister 60 unit(s) blister 56 unit(s)	20 mg 20 mg	1.2 1.12	N06AB03 N06AB03	20 mg 20 mg	60 56
	Fluoxetina Fluoxetina	oral solution capsule	bottle 1x 140 ml blister 10 unit(s)	4 mg/ml 20 mg	0.56 0.2	N06AB03 N06AB03	20 mg 20 mg	28 10
	Fluoxetina	capsule	blister 20 unit(s)	20 mg	0.4	N06AB03	20 mg	28 10 20 14
	Fluoxetina Fluoxetina	capsule capsule	blister 14 unit(s) blister 50 unit(s)	20 mg 20 mg	0.28 1	N06AB03 N06AB03	20 mg 20 mg	14 50
	Fluoxetina Fluvoxamina	capsule film coated tablet	blister 28 unit(s) blister 60 unit(s)	20 mg 50 mg	0.56 3	N06AB03 N06AB08	20 mg 100 mg	50 28 30
	Fluvoxamina	film coated tablet	blister 60 unit(s)	100 mg	6	N06AB08	100 mg	60 5 10
	Fluvoxamina Fluvoxamina	film coated tablet film coated tablet	blister 10 unit(s) blister 20 unit(s)	50 mg 50 mg	0.5 1	N06AB08 N06AB08	100 mg 100 mg	5 10
	Imipramina Imipramina	coated tablet coated tablet	blister 60 unit(s) blister 60 unit(s)	25 mg 10 mg	1.5 0.6	N06AA02 N06AA02	100 mg 100 mg	15 6
	Maprotilina	film coated tablet coated tablet	blister 60 unit(s) blister 60 unit(s)	75 mg	4.5	N06AA21 N06AA21	100 mg	45
	Maprotilina Maprotilina	coated tablet	blister 60 unit(s)	50 mg 25 mg	3 1.5	NU6AA21	100 mg 100 mg	45 30 15
	Maprotilina Maprotilina	film coated tablet coated tablet	blister 60 unit(s) blister 60 unit(s)	50 mg 75 mg	3 4.5	N06AA21 N06AA21	100 mg 100 mg	30
	Maprotilina	coated tablet	blister 10 unit(s) blister 60 unit(s)	25 mg	0.25	N06AA21 N06AA21	100 mg	45 2.5 15 5
	Maprotilina Mianserina	film coated tablet coated tablet	blister 10 unit(s)	25 mg 30 mg	1.5 0.3	NU6AXU3	100 mg 60 mg	5
	Mianserina Milnaciprano	coated tablet capsule	blister 60 unit(s) blister 56 unit(s)	30 mg 25 mg	1.8 1.4	N06AX03 N06AX17	60 mg 100 mg	30
	Milnaciprano	capsule	blister 56 unit(s)	50 mg	2.8	N06AX17	100 mg	14 28 15 15 30 60
	Mirtazapina Mirtazapina	orodispersible tablet film coated tablet	blister 30 unit(s) blister 30 unit(s)	15 mg 15 mg	0.45 0.45	N06AX11 N06AX11	30 mg 30 mg	15
	Mirtazapina Mirtazapina	orodispersible tablet film coated tablet	blister 60 unit(s) blister 60 unit(s)	15 mg 30 mg	0.9 1.8	N06AX11 N06AX11	30 mg 30 mg	30 60
	Mirtazapina	orodispersible tablet coated tablet	blister 60 unit(s) blister 30 unit(s)	30 mg	1.8	N06AX11	30 mg	60
	Mirtazapina Mirtazapina	orodispersible tablet	blister 30 unit(s)	30 mg 30 mg	0.9	N06AX11 N06AX11	30 mg 30 mg	30
	Mirtazapina Mirtazapina	film coated tablet coated tablet	blister 30 unit(s) blister 56 unit(s)	30 mg 15 mg	0.9 0.84	N06AX11 N06AX11	30 mg 30 mg	30 28
	Mirtazapina Mirtazapina	coated tablet film coated tablet	blister 56 unit(s) blister 56 unit(s)	30 mg 15 mg	1.68 0.84	N06AX11 N06AX11	30 mg 30 mg	56
	Mirtazapina	film coated tablet	blister 60 unit(s)	15 mg	0.9	N06AX11	30 mg	30
	Mirtazapina Mirtazapina	orodispersible tablet film coated tablet	blister 30 unit(s) blister 56 unit(s)	45 mg 30 mg	1.35 1.68	N06AX11 N06AX11	30 mg 30 mg	60 30 30 30 28 56 28 30 45
	Mirtazapina Mirtazapina	orodispersible tablet coated tablet	blister 18 unit(s) blister 14 unit(s)	15 mg 15 mg	0.27 0.21	N06AX11 N06AX11	30 mg 30 mg	9 7 10
	Mirtazapina	orodispersible tablet	blister 20 unit(s)	15 mg	0.3	N06AX11	30 mg	10
	Mirtazapina Mirtazapina	orodispersible tablet film coated tablet	blister 20 unit(s) blister 10 unit(s)	30 mg 15 mg	0.6 0.15	N06AX11 N06AX11	30 mg 30 mg	20 5
	Mirtazapina Mirtazapina	film coated tablet orodispersible tablet	blister 20 unit(s) blister 6 unit(s)	15 mg 15 mg	0.3 0.09	N06AX11 N06AX11	30 mg 30 mg	10 3
	Mirtazapina	film coated tablet	blister 20 unit(s)	30 mg	0.6	N06AX11	30 mg	20 7
	Mirtazapina Mirtazapina	film coated tablet film coated tablet	blister 14 unit(s) blister 10 unit(s)	15 mg 30 mg	0.21 0.3	N06AX11 N06AX11	30 mg 30 mg	10
	Mirtazapina Mirtazapina	film coated tablet film coated tablet	blister 15 unit(s) blister 15 unit(s)	30 mg 15 mg	0.45 0.225	N06AX11 N06AX11	30 mg 30 mg	15 7.5
	Mirtazapina	coated tablet	blister 10 unit(s)	30 mg	0.3	N06AX11	30 mg	15 7.5 10
	Mirtazapina Mirtazapina	film coated tablet orodispersible tablet	blister 14 unit(s) thermowelded tape 30 unit(s)	30 mg 30 mg	0.42 0.9	N06AX11 N06AX11	30 mg 30 mg	14 30
	Mirtazapina Mirtazapina	orodispersible tablet orodispersible tablet	thermowelded tape 30 unit(s) thermowelded tape 6 unit(s)	15 mg 15 mg	0.45 0.09	N06AX11 N06AX11	30 mg 30 mg	15 3
	Mirtazapina	film coated tablet film coated tablet	blister 28 unit(s)	30 mg	0.84	N06AX11 N06AX11	30 mg	28 14
	Mirtazapina Moclobemida	film coated tablet	blister 28 unit(s) blister 60 unit(s)	15 mg 150 mg	0.42 9	N06AG02	30 mg 300 mg	30
	Moclobemida Moclobemida	film coated tablet film coated tablet	blister 60 unit(s) blister 20 unit(s)	300 mg 150 mg	18 3	N06AG02 N06AG02	300 mg 300 mg	60 10
	Moclobemida Nortriptilina	film coated tablet coated tablet	blister 10 unit(s) blister 60 unit(s)	150 mg 25 mg	1.5 1.5	N06AG02 N06AA10	300 mg 75 mg	5 20
	Nortriptilina	coated tablet	blister 20 unit(s)	25 mg	0.5	N06AA10	75 mg	6.67
	Paroxetina Paroxetina	pill film coated tablet	blister 60 unit(s) blister 60 unit(s)	20 mg 20 mg	1.2 1.2	N06AB05 N06AB05	20 mg 20 mg	60 60
	Paroxetina Paroxetina	film coated tablet oral drops - solution	bottle 60 unit(s) bottle 1x 30 ml	20 mg 10 mg/ml	1.2	N06AB05 N06AB05	20 mg 20 mg	60 15 20
	Paroxetina	film coated tablet	blister 20 unit(s)	20 mg	0.4	N06AB05	20 mg	20
	Paroxetina Paroxetina	film coated tablet film coated tablet	blister 10 unit(s) bottle 10 unit(s)	20 mg 20 mg	0.2 0.2	N06AB05 N06AB05	20 mg 20 mg	10
	Paroxetina Paroxetina	pill	blister 10 unit(s) bottle 30 unit(s)	20 mg 20 mg	0.2	N06AB05	20 mg 20 mg	10 30 30 20
	Paroxetina	film coated tablet film coated tablet	blister 30 unit(s)	20 mg	0.6	N06AB05	20 mg	30
	Paroxetina Pirlindol	pill pill	blister 20 unit(s) bottle 60 unit(s)	20 mg 50 mg	0.4 3	N06AB05 -	20 mg 200 mg	15
	Pirlindol Pirlindol	pill pill	blister 60 unit(s) blister 60 unit(s)	100 mg 75 mg	6 4.5	-	200 mg 200 mg	30 22.5
	Pirlindol	pill	bottle 20 unit(s)	50 mg	1	-	200 mg	5
	Reboxetina Reboxetina	pill pill	blister 60 unit(s) blister 20 unit(s)	4 mg 4 mg	0.24 0.08	N06AX18 N06AX18	8 mg 8 mg	30 10
	Sertralina Sertralina	film coated tablet film coated tablet	blister 60 unit(s) blister 56 unit(s)	50 mg 50 mg	3 2.8	N06AB06 N06AB06	50 mg 50 mg	60 56
	Sertralina	film coated tablet	blister 60 unit(s)	100 mg	6	N06AB06	50 mg	120
	Sertralina Sertralina	film coated tablet film coated tablet	blister 56 unit(s) blister 20 unit(s)	100 mg 50 mg	5.6 1	N06AB06 N06AB06	50 mg 50 mg	112 20
	Sertralina	film coated tablet	blister 10 unit(s)	50 mg	0.5	N06AB06	50 mg	10
	Sertralina Sertralina	film coated tablet concentrate for oral solution	blister 14 unit(s) bottle 1x 60 ml	50 mg 20 mg/ml	0.7 1.2	N06AB06 N06AB06	50 mg 50 mg	14 24
	Sertralina Sertralina	film coated tablet film coated tablet	blister 30 unit(s) blister 30 unit(s)	50 mg 100 mg	1.5	N06AB06 N06AB06	50 mg 50 mg	14 24 30 60
	Trazodona	modified release tablet	blister 60 unit(s)	150 mg	3 9 3	N06AX05	300 mg	30
	Trazodona Trazodona	modified release tablet film coated tablet	blister 20 unit(s) blister 60 unit(s)	150 mg 100 mg	3 6	N06AX05 N06AX05	300 mg 300 mg	10
	Trazodona	prolonged release tablet	blister 30 unit(s)	300 mg	6 9 9	N06AX05	300 mg	20 30
	Trazodona	pill	blister 60 unit(s)	150 mg		N06AX05	300 mg	30

lass	active drug	mode	box	dosage per unit	total dosage (g)	ATC code	DDD	DDDs p packag
ntidepressants	Trazodona Trazodona	prolonged release tablet	blister 10 unit(s)	150 mg	1.5	NO6AX05	300 mg	5
	Trazodona	film coated tablet pill	blister 20 unit(s) blister 20 unit(s)	100 mg 100 mg	2	N06AX05 N06AX05	300 mg 300 mg	6.67 6.67
		pill	blister 20 unit(s)	150 mg	3	N06AX05	300 mg	10
	Trimipramina Trimipramina	pill coated tablet	blister 60 unit(s) blister 60 unit(s)	25 mg 100 mg	1.5 6	N06AA06 N06AA06	150 mg 150 mg	10 40
	Trimipramina	pill prolonged release tablet	blister 10 unit(s)	25 mg	0.25	N06AA06	150 mg	1.67
	Venlafaxina Venlafaxina	prolonged release tablet	blister 30 unit(s) blister 30 unit(s)	150 mg 37.5 mg	4.5 1.125	N06AX16 N06AX16	100 mg 100 mg	45 11.25
	Venlafaxina	extended release capsule	blister 30 unit(s)	75 mg	2.25	N06AX16	100 mg	22.5
	Venlafaxina Venlafaxina	extended release capsule prolonged release tablet	blister 30 unit(s) blister 30 unit(s)	150 mg 225 mg	4.5 6.75	N06AX16 N06AX16	100 mg 100 mg	45 67.5
	Venlafaxina	film coated tablet	blister 60 unit(s)	75 mg	4.5	N06AX16	100 mg	45
	Venlafaxina	prolonged release tablet	blister 30 unit(s)	75 mg	2.25	N06AX16	100 mg	22.5
	Venlafaxina Venlafaxina	extended release capsule extended release capsule	blister 30 unit(s) blister 30 unit(s)	37.5 mg 225 mg	1.125 6.75	N06AX16 N06AX16	100 mg 100 mg	11.25 67.5
	Venlafaxina	film coated tablet	blister 60 unit(s)	37.5 mg	2.25	N06AX16	100 mg	22.5
	Venlafaxina Venlafaxina	extended release capsule prolonged release tablet	blister 10 unit(s) blister 10 unit(s)	75 mg 37.5 mg	0.75 0.375	N06AX16 N06AX16	100 mg 100 mg	7.5 3.75
	Venlafaxina	extended release capsule	blister 10 unit(s)	37.5 mg	0.375	N06AX16	100 mg	3.75
	Venlafaxina Venlafaxina	prolonged release tablet extended release capsule	blister 10 unit(s) blister 20 unit(s)	75 mg 37.5 mg	0.75 0.75	N06AX16 N06AX16	100 mg 100 mg	7.5 7.5
	Venlafaxina	film coated tablet	blister 10 unit(s)	37.5 mg	0.375	N06AX16	100 mg	3.75
	Venlafaxina Vortioxetina	oral solution film coated tablet	bottle 1x 60 ml blister 28 unit(s)	75 mg/ml 10 mg	4.5 0.28	N06AX16 N06AX26	100 mg 10 mg	45 28
	Vortioxetina	film coated tablet	blister 28 unit(s)	20 mg	0.56	N06AX26	10 mg	56
	Vortioxetina Vortioxetina	film coated tablet film coated tablet	blister 28 unit(s) blister 14 unit(s)	5 mg 5 mg	0.14 0.07	N06AX26 N06AX26	10 mg 10 mg	14 7
	Vortioxetina Vortioxetina	oral drops - solution film coated tablet	bottle 1x 15 ml blister 28 unit(s)	20 mg/ml 15 mg	0.3 0.42	N06AX26 N06AX26	10 mg 10 mg	30 42
tipsychotics	Amissulprida	oral solution	ampoule 20 unit(s) 10 ml	50 mg/10 ml	1	N05AL05	0.4 g	2.5
	Amissulprida	pill pill	blister 60 unit(s) blister 20 unit(s)	50 mg 50 mg	3	N05AL05 N05AL05	0.4 g 0.4 g	7.5 2.5
	Amissulprida	pill	blister 60 unit(s)	200 mg	12	N05AL05	0.4 g	30
	Aripiprazol	pill	blister 28 unit(s)	10 mg	0.28	N05AX12	15 mg	18.67
	Aripiprazol Aripiprazol	prolonged-release injection pill	vial 1x 1.9 ml blister 28 unit(s)	400 mg 15 mg	0 0.42	N05AX12 N05AX12	13,3 mg 15 mg	30.08 28
	Aripiprazol	pill	blister 28 unit(s)	5 mg 1 mg/ml	0.14	N05AX12	15 mg	9.33
	Aripiprazol Aripiprazol	oral solution pill	bottle 1x 150 ml blister 14 unit(s)	1 mg/ml 10 mg	0.15 0.14	N05AX12 N05AX12	15 mg 15 mg	10 9.33
	Aripiprazol	pill	blister 14 unit(s)	5 mg	0.07	N05AX12	15 mg	4.67
	Aripiprazol Aripiprazol	pill injectable solution	blister 14 unit(s) vial 1x 1.3 ml	15 mg 7.5 mg/ml	0.21 0	N05AX12 N05AX12	15 mg 15 mg	14 0.65
	Ciamemazina	oral drops - solution	bottle 1x 30 ml	40 mg/ml	1.2	N05AA06	100 mg	12
	Ciamemazina Ciamemazina	coated tablet coated tablet	blister 60 unit(s) blister 20 unit(s)	100 mg	6	N05AA06 N05AA06	100 mg 100 mg	60 20
	Cloropromazina	coated tablet	blister 20 unit(s) blister 20 unit(s)	100 mg 25 mg	0.5	N05AA01	300 mg	1.67
	Cloropromazina	coated tablet coated tablet	blister 60 unit(s) blister 60 unit(s)	25 mg	1.5	N05AA01	300 mg	5
	Cloropromazina	coated tablet oral drops - solution		100 mg 40 mg/ml	6 1.2	N05AA01 N05AA01	300 mg 300 mg	20 4
	Cloropromazina	injectable solution	dropper bottle 1x 30 ml ampoule 5 unit(s) 2 ml	50 mg/2 ml	0.25	N05AA01	100 mg	4 2.5
	Cloropromazina Clorpromazina	injectable solution coated tablet	ampoule 6 unit(s) 5 ml blister 60 unit(s)	25 mg/5 ml 100 mg	0.15 6	N05AA01 N05AA01	100 mg 300 mg	1.5 20
	Clorpromazina	coated tablet	blister 60 unit(s)	25 mg	1.5	N05AA01	300 mg	5
	Clorpromazina	coated tablet	blister 20 unit(s)	25 mg	0.5 1.2	N05AA01 N05AA01	300 mg	1.67 4
	Clorpromazina Clorpromazina	oral drops - solution injectable solution	dropper bottle 1x 30 ml ampoule 6 unit(s) 5 ml	40 mg/ml 25 mg/5 ml	0.15	N05AA01	300 mg 100 mg	1.5
	Clorpromazina	injectable solution	ampoule 5 unit(s) 2 ml	50 mg/2 ml	0.25	N05AA01	100 mg	2.5
	Flufenazina Flupentixol	injectable solution injectable solution	ampoule 1x 1 ml ampoule 1x 1 ml	25 mg/ml 100 mg/1 ml	0.025 0.1	N05AB02 N05AF01	1 mg 4 mg	25 25
	Flupentixol	injectable solution	ampoule 5 unit(s) 1 ml	20 mg/1 ml	0.1	N05AF01	4 mg	25
	Haloperidol Haloperidol	oral solution	bottle 1x 30 ml blister 60 unit(s)	2 mg/ml	0.06 0.06	N05AD01 N05AD01	8 mg	7.5 7.5
	Haloperidol	pill pill	blister 60 unit(s)	1 mg 5 mg	0.3	N05AD01	8 mg 8 mg	37.5
	Haloperidol Haloperidol	injectable solution	ampoule 1x 1 ml	100 mg/1 ml 50 mg/1 ml	0.1	N05AD01	3.3 mg	30.3
	Haloperidol	injectable solution pill	ampoule 1x 1 ml blister 60 unit(s)	10 mg/1 mt	0.05 0.6	N05AD01 N05AD01	3.3 mg 8 mg	15.15 75
	Haloperidol	pill	blister 20 unit(s)	1 mg	0.02	N05AD01	8 mg	2.5
	Haloperidol Haloperidol	injectable solution pill	ampoule 5 unit(s) 1 ml blister 60 unit(s)	5 mg/1 ml	0.025 0.12	N05AD01 N05AD01	8 mg	3.125 15
	Levomepromazina	oral drops - solution	bottle 1x 30 ml	2 mg 40 mg/ml	1.2	N05AA02	8 mg 300 mg	4
	Levomepromazina	coated tablet	blister 60 unit(s)	100 mg	6	N05AA02	300 mg	20
	Levomepromazina Levomepromazina		blister 60 unit(s) blister 20 unit(s)	25 mg 25 mg	1.5 0.5	N05AA02 N05AA02	300 mg 300 mg	5 1.67
	Levomepromazina	injectable solution	ampoule 6 unit(s) 1 ml	25 mg/1 ml	0.15	N05AA02	100 mg	1.5
	Melperona Melperona	film coated tablet film coated tablet	bottle 60 unit(s) bottle 60 unit(s)	25 mg 50 mg	1.5 3	N05AD03 N05AD03	300 mg 300 mg	5 10
	Melperona	film coated tablet	bottle 20 unit(s)	25 mg	0.5	N05AD03	300 mg	1.67
	Olanzapina Olanzapina	film coated tablet orodispersible tablet	blister 28 unit(s) blister 28 unit(s)	2.5 mg 10 mg	0.07 0.28	N05AH03 N05AH03	10 mg 10 mg	7 28
	Olanzapina	pill	blister 28 unit(s)	5 mg	0.14	N05AH03	10 mg	14
	Olanzapina	pill	blister 28 unit(s)	10 mg	0.28	N05AH03	10 mg	28
	Olanzapina Olanzapina	orodispersible tablet film coated tablet	blister 28 unit(s) blister 28 unit(s)	5 mg 10 mg	0.14 0.28	N05AH03 N05AH03	10 mg 10 mg	14 28
	Olanzapina	pill	blister 28 unit(s)	2.5 mg	0.07	N05AH03	10 mg	7
	Olanzapina Olanzapina	coated tablet coated tablet	blister 28 unit(s) blister 28 unit(s)	2.5 mg 5 mg	0.07 0.14	N05AH03 N05AH03	10 mg 10 mg	7 14
	Olanzapina	film coated tablet	blister 28 unit(s)	5 mg	0.14	NUEVINO	10 mg	1.4
	Olanzapina	coated tablet	blister 28 unit(s)	10 mg	0.28 0.56	N05AH03 N05AH03 N05AH03	10 mg	28 56 42
	Olanzapina Olanzapina	orodispersible tablet pill	blister 28 unit(s) blister 28 unit(s)	20 mg 15 mg	0.42	N05AH03	10 mg 10 mg	42
	Olanzapina	orodispersible tablet	blister 28 unit(s)	15 mg	0.42	N05AH03	10 mg	
	Olanzapina Olanzapina	film coated tablet pill	blister 28 unit(s) blister 28 unit(s)	7.5 mg 7.5 mg	0.21 0.21	N05AH03 N05AH03	10 mg 10 mg	21 21 42
	Olanzapina	coated tablet	blister 28 unit(s)	15 mg	0.42	N05AH03	10 mg	42
	Olanzapina Olanzapina	coated tablet film coated tablet	blister 28 unit(s) blister 28 unit(s)	7.5 mg 15 mg	0.21 0.42	N05AH03 N05AH03	10 mg 10 mg	21 42
	Olanzapina	film coated tablet	blister 14 unit(s)	5 mg	0.07	N05AH03	10 mg	7
	Olanzapina	pill prolonged release injection	blister 14 unit(s)	2.5 mg	0.035	N05AH03	10 mg	3.5
	Paliperidona Paliperidona	prolonged release tablet	pre-filled syringe 1x blister 28 unit(s)	150 mg 3 mg	0.15 0.084	N05AX13 N05AX13	2.5 mg 6 mg	60 14
	Paliperidona	prolonged release injection	pre-filled syringe 1x	100 mg	0.1	N05AX13	2.5 mg	40
	Paliperidona Paliperidona	prolonged release tablet prolonged release tablet	blister 28 unit(s) blister 28 unit(s)	6 mg 9 mg	0.168 0.252	N05AX13 N05AX13	6 mg 6 mg	28 42
	Paliperidona	prolonged release injection	pre-filled syringe 1x 0.875 ml	175 mg	0	N05AX13	2.5 mg	70
	Paliperidona Paliperidona	prolonged release injection prolonged release injection	pre-filled syringe 1x 2.625 ml pre-filled syringe 1x 1.75 ml	525 mg 350 mg	0	N05AX13 N05AX13	2.5 mg	210 140
	Paliperidona	prolonged release injection	pre-filled syringe 1x	50 mg	0.05	N05AX13	2.5 mg 2.5 mg	20
	Paliperidona	prolonged release injection	pre-filled syringe 1x	75 mg	0.075	N05AX13 N05AX13	2.5 mg	30
	Paliperidona Paliperidona	prolonged release injection prolonged release tablet	pre-filled syringe 1x 1.315 ml blister 14 unit(s)	263 mg 3 mg	0 0.042	N05AX13	2.5 mg 6 mg	105.2 7
	Pimozida	pill	blister 60 unit(s)	4 mg	0.24	N05AG02	4 mg	60
	Pimozida Quetiapina	pill prolonged release tablet	blister 20 unit(s) blister 60 unit(s)	4 mg 50 mg	0.08 3	N05AG02 N05AH04	4 mg 400 mg	20 7.5
	Quetiapina	film coated tablet	blister 20 unit(s)	25 mg	0.5	N05AH04	400 mg	1.25
	Quetiapina	film coated tablet	blister 60 unit(s)	100 mg	6	N05AH04	400 mg	15
	Quetiapina Quetiapina	prolonged release tablet prolonged release tablet	blister 60 unit(s) blister 30 unit(s)	300 mg 150 mg	18 4.5	N05AH04 N05AH04	400 mg 400 mg	45 11.25
	Quetianina	film coated tablet	blister 60 unit(s)	200 mg 200 mg	12	N05AH04	400 mg 400 mg	30
	Quetiapina	prolonged release tablet film coated tablet	blister 60 unit(s)	200 mg	12	N05AH04	400 mg	30
	Quetiapina Quetiapina	film coated tablet prolonged release tablet	blister 60 unit(s) blister 60 unit(s)	300 mg 400 mg	18 24	N05AH04 N05AH04	400 mg 400 mg	45 60
	Quetiapina	film coated tablet	blister 10 unit(s)	25 mg	0.25	N05AH04	400 mg	0.625
	Quetiapina	prolonged release tablet	blister 10 unit(s) blister 10 unit(s)	50 mg	0.5	N05AH04 N05AH04	400 mg 400 mg	1.25 5
	Quetiapina Quetiapina	prolonged release tablet film coated tablet	blister 6 unit(s)	200 mg 25 mg	0.15	N05AH04	400 mg	0.375
	Quetiapina	prolonged release tablet	blister 10 unit(s)	300 mg	3	N05AH04	400 mg	7.5
	Quetiapina	film coated tablet	blister 10 unit(s)	25mg+100mg+2	00ო დ 65	N05AH04 N05AH04	400 mg	1.625
	Quetiapina Risperidona	prolonged release tablet film coated tablet	bottle 10 unit(s) blister 60 unit(s)	200 mg 0.5 mg	2 0.03	N05AX08	400 mg 5 mg	5 6
	B	oral solution	bottle 1x 30 ml	1 mg/ml	0.03	N05AX08	5 mg	6
	Risperidona							
	Risperidona	film coated tablet	blister 60 unit(s)	2 mg	0.12	N05AX08 N05AX08	5 mg	24
	Risperidona Risperidona Risperidona Risperidona Risperidona	film coated tablet film coated tablet prolonged release injection film coated tablet	blister 60 unit(s) blister 60 unit(s) vial 1x 2 ml blister 60 unit(s)	2 mg 1 mg 37.5 mg/2 ml 3 mg	0.12 0.06 0.0375 0.18	N05AX08 N05AX08 N05AX08 N05AX08	5 mg 5 mg 2.7 mg 5 mg 2.7 mg	24 12 13.89 36 9.26

ass	active drug	mode	box	dosage per unit	total dosage (g)	ATC code	DDD	DDDs po package
ntipsychotics	Risperidona Risperidona	orodispersible tablet orodispersible tablet	blister 60 unit(s) blister 60 unit(s)	0.5 mg 1 mg 50 mg/2 ml	0.03 0.06	N05AX08 N05AX08	5 mg 5 mg	6 12
	Risperidona Risperidona	prolonged release injection orodispersible tablet	vial 1x 2 ml blister 60 unit(s)	50 mg/2 ml 2 mg	0.05 0.12	N05AX08 N05AX08	2.7 mg 5 mg	18.52 24
	Risperidona Risperidona	orodispersible tablet film coated tablet	blister 28 unit(s) blister 60 unit(s)	2 mg 4 mg	0.056 0.24	N05AX08 N05AX08	5 mg 5 mg	11.2 48
	Risperidona Risperidona	film coated tablet orodispersible tablet	blister 20 unit(s) blister 56 unit(s)	0.5 mg 3 mg	0.01 0.168	N05AX08 N05AX08	5 mg 5 mg	33.6
	Risperidona Risperidona	orodispersible tablet orodispersible tablet	blister 56 unit(s) blister 20 unit(s)	2 mg 0.5 mg	0.112 0.01	N05AX08 N05AX08	5 mg 5 mg	22.4 2
	Risperidona	film coated tablet	blister 20 unit(s)	1 mg	0.02	N05AX08	5 mg	4
	Risperidona Risperidona	orodispersible tablet orodispersible tablet	blister 56 unit(s) blister 20 unit(s)	4 mg 1 mg	0.224 0.02	N05AX08 N05AX08	5 mg 5 mg	44.8 4
	Risperidona Risperidona	orodispersible tablet orodispersible tablet	blister 14 unit(s) blister 14 unit(s)	2 mg 0.5 mg	0.028 0.007	N05AX08 N05AX08	5 mg 5 mg	5.6 1.4
	Risperidona Risperidona	orodispersible tablet orodispersible tablet	blister 56 unit(s) blister 56 unit(s)	0.5 mg 1 mg	0.028 0.056	N05AX08 N05AX08	5 mg 5 mg	5.6 11.2
	Risperidona Risperidona	powder injectable suspension	vial 1x 2 ml vial 1x 2 ml	25 mg/2 ml	0.025 0.05	N05AX08 N05AX08	2.7 mg	9.26 18.52
	Risperidona Sulpirida	powder injectable suspension powder injectable suspension pill	vial 1x 2 ml blister 60 unit(s)	50 mg/2 ml 37.5 mg/2 ml 200 mg	0.0375 12	N05AX08 N05AL01	2.7 mg 2.7 mg 800 mg	13.89 15
	Sulpirida Sulpirida	capsule capsule	blister 60 unit(s) blister 20 unit(s)	50 mg 50 mg	3	N05AL01 N05AL01	800 mg 800 mg	3.75 1.25
	Tiaprida	pill	blister 60 unit(s)	100 mg	6	N05AL03	400 mg	15
	Tiaprida Tiaprida	pill injectable solution	blister 20 unit(s) ampoule 6 unit(s) 2 ml	100 mg 100 mg/2 ml	2 0.6	N05AL03 N05AL03	400 mg 400 mg	5 1.5
	Ziprasidona Ziprasidona	capsule capsule	blister 56 unit(s) blister 56 unit(s)	60 mg 40 mg	3.36 2.24	N05AE04 N05AE04	80 mg 80 mg	42 28
	Ziprasidona Ziprasidona	capsule capsule	blister 56 unit(s) blister 56 unit(s)	80 mg 20 mg	4.48 1.12	N05AE04 N05AE04	80 mg 80 mg	56 14 7
	Ziprasidona Ziprasidona	capsule capsule	blister 14 unit(s) blister 14 unit(s)	40 mg 20 mg	0.56 0.28	N05AE04 N05AE04	80 mg 80 mg	7 3.5
	Zotepina Zotepina	coated tablet coated tablet	blister 60 unit(s) blister 60 unit(s)	100 mg 25 mg	6 1.5	N05AX11 N05AX11	200 mg 200 mg	3.5 30 7.5
	Zotepina	coated tablet	blister 60 unit(s)	50 mg	3	N05AX11	200 mg	15
	Zotepina Zuclopentixol Zuclopentixol	coated tablet injectable solution injectable solution	blister 20 unit(s) ampoule 1x 1 ml ampoule 1x 1 ml	25 mg 200 mg/1 ml 50 mg/1 ml	0.5 0.2 0.05	N05AX11 N05AF05 N05AF05	200 mg 30 mg 30 mg	2.5 6.67 1.67
odiazepines	Alprazolam	pill	blister 60 unit(s)	0.5 mg	0.03	N05BA12	1 mg	30
	Alprazolam Alprazolam	modified release tablet pill	blister 60 unit(s) blister 60 unit(s)	1 mg 0.25 mg	0.06 0.015	N05BA12 N05BA12	1 mg 1 mg	60 15
	Alprazolam Alprazolam	pill modified release tablet	blister 60 unit(s) blister 60 unit(s)	1 mg 2 mg	0.06 0.12	N05BA12 N05BA12	1 mg 1 mg	60 120
	Alprazolam Alprazolam	modified release tablet pill	blister 60 unit(s) blister 20 unit(s)	0.5 mg 0.25 mg	0.03 0.005	N05BA12 N05BA12	1 mg 1 mg	30 5
	Alprazolam Alprazolam	pill	blister 20 unit(s) blister 20 unit(s)	1 mg	0.003 0.02 0.01	N05BA12 N05BA12	1 mg	20 10
	Alprazolam	pill modified release tablet	blister 20 unit(s)	0.5 mg 1 mg	0.02	N05BA12	1 mg 1 mg	20 10
	Alprazolam Alprazolam	modified release tablet modified release tablet	blister 20 unit(s) blister 60 unit(s)	0.5 mg 3 mg	0.01 0.18	N05BA12 N05BA12	1 mg 1 mg	180
	Alprazolam Alprazolam	modified release tablet modified release tablet	blister 40 unit(s) blister 40 unit(s)	0.5 mg 1 mg	0.02 0.04	N05BA12 N05BA12	1 mg 1 mg	20 40
	Alprazolam Alprazolam	modified release tablet modified release tablet	blister 20 unit(s) blister 20 unit(s)	2 mg 3 mg	0.04 0.06	N05BA12 N05BA12	1 mg 1 mg	40 60
	Alprazolam Alprazolam	sublingual tablet sublingual tablet	blister 10 unit(s) blister 20 unit(s)	0.5 mg 0.5 mg	0.005 0.01	N05BA12 N05BA12	1 mg 1 mg	5 10
	Alprazolam	sublingual tablet	blister 60 unit(s)	0.5 mg	0.03	N05BA12 N05BA12	1 mg	30 60
	Alprazolam Bromazepam	sublingual tablet pill	blister 60 unit(s) blister 40 unit(s)	1 mg 1.5 mg	0.06	N05BA08	1 mg 10 mg	6
	Bromazepam Bromazepam	pill pill	blister 60 unit(s) blister 40 unit(s)	1.5 mg 3 mg	0.09 0.12	N05BA08 N05BA08	10 mg 10 mg	9 12
	Bromazepam Bromazepam	pill pill	blister 60 unit(s) blister 60 unit(s)	3 mg 6 mg	0.18 0.36	N05BA08 N05BA08	10 mg 10 mg	18 36 24
	Bromazepam Bromazepam	pill capsule	blister 40 unit(s) blister 60 unit(s)	6 mg 3 mg	0.24 0.18	N05BA08 N05BA08	10 mg 10 mg	24 18
	Bromazepam Bromazepam	capsule pill	blister 60 unit(s) blister 20 unit(s)	1.5 mg	0.09	N05BA08 N05BA08	10 mg 10 mg	9
	Bromazepam	pill	blister 20 unit(s)	3 mg 6 mg	0.12	N05BA08	10 mg	12
	Bromazepam Bromazepam	capsule pill	blister 20 unit(s) blister 20 unit(s)	1.5 mg 1.5 mg	0.03 0.03	N05BA08 N05BA08	10 mg 10 mg	3 3 6
	Bromazepam Brotizolam	capsule pill	blister 20 unit(s) blister 14 unit(s)	3 mg 0.25 mg	0.06 0.0035	N05BA08 N05CD09	10 mg 0.25 mg	14
	Cetazolam Cetazolam	capsule capsule	bottle 60 unit(s) bottle 60 unit(s)	15 mg 30 mg	0.9 1.8	N05BA10 N05BA10	30 mg 30 mg	30 60
	Cetazolam Cetazolam	capsule capsule	bottle 20 unit(s) bottle 20 unit(s)	30 mg 15 mg	0.6 0.3	N05BA10 N05BA10	30 mg 30 mg	20
	Clobazam Clobazam	pill pill	blister 30 unit(s) blister 30 unit(s)	10 mg 20 mg	0.3 0.6	N05BA09 N05BA09	20 mg 20 mg	10 15 30
	Clobazam Clobazam	pill pill	blister 20 unit(s)	20 mg 10 mg	0.4 0.2	N05BA09 N05BA09	20 mg 20 mg	20 10
	Dip. chlorazepate	capsule	blister 20 unit(s) blister 60 unit(s)	10 mg	0.6	N05BA05	20 mg	30 15
	Dip. chlorazepate Dip. chlorazepate	capsule capsule	blister 60 unit(s) blister 60 unit(s)	5 mg 15 mg	0.3 0.9	N05BA05 N05BA05	20 mg 20 mg	45
	Dip. chlorazepate Dip. chlorazepate	capsule capsule	blister 20 unit(s) blister 20 unit(s)	10 mg 5 mg	0.2 0.1	N05BA05 N05BA05	20 mg 20 mg	10 5
	Dip. chlorazepate Chlorodiazepoxide	capsule coated tablet	blister 20 unit(s) blister 60 unit(s)	15 mg 5 mg	0.3	N05BA05 N05BA02	20 mg 30 mg	15 10
	Chlorodiazepoxide Chlorodiazepoxide	coated tablet coated tablet	blister 60 unit(s) blister 20 unit(s)	10 mg 5 mg	0.6 0.1	N05BA02 N05BA02	30 mg 30 mg	20 3.33
	Cloxazolam	pill pill	blister 60 unit(s) blister 60 unit(s) blister 20 unit(s)	2 mg	0.12 0.06	N05BA22 N05BA22	6 mg	20 10
	Cloxazolam Cloxazolam	pill	blister 20 unit(s)	1 mg 2 mg	0.04	N05BA22	6 mg 6 mg	6.67
	Cloxazolam Diazepam	pill pill	blister 20 unit(s) blister 60 unit(s)	1 mg 5 mg	0.02 0.3	N05BA22 N05BA01	6 mg 10 mg	3.33 30
	Diazepam Diazepam	pill pill	blister 25 unit(s) blister 60 unit(s)	10 mg 10 mg	0.25 0.6	N05BA01 N05BA01	10 mg 10 mg	25 60
	Diazepam Diazepam	pill pill	blister 20 unit(s) blister 25 unit(s)	5 mg 5 mg	0.1 0.125	N05BA01 N05BA01	10 mg 10 mg	10 12.5
	Diazepam Diazepam	capsule pill	blister 60 unit(s) blister 20 unit(s)	6 mg 10 mg	0.36 0.2	N05BA01 N05BA01	10 mg 10 mg	36 20
	Diazepam	extended release capsule	blister 60 unit(s)	10 mg	0.6	N05BA01	10 mg	60
	Diazepam Diazepam	pill extended release capsule	blister 40 unit(s) blister 20 unit(s)	5 mg 10 mg	0.2 0.2	N05BA01 N05BA01	10 mg 10 mg	20 20
	Diazepam Diazepam	pill capsule	blister 40 unit(s) blister 60 unit(s)	10 mg 3 mg	0.4 0.18	N05BA01 N05BA01	10 mg 10 mg	40 18
	Diazepam Diazepam	capsule rectal solution	blister 20 unit(s) cannula 5 unit(s) 2.5 ml	3 mg 5 mg/2.5 ml	0.06 0.025	N05BA01 N05BA01	10 mg 10 mg	6 2.5
	Diazepam Diazepam	rectal solution capsule	cannula 5 unit(s) 2.5 ml blister 20 unit(s)	10 mg/2.5 ml	0.05 0.12	N05BA01 N05BA01	10 mg 10 mg	5 12
	Diazepam	rectal solution	unidosage 4 unit(s) 2.5 ml	6 mg 5 mg/2.5 ml	0.02	N05BA01 N05CD04	10 mg	2
	Estazolam Estazolam	pill pill	blister 14 unit(s) blister 28 unit(s) blister 20 unit(s)	2 mg 2 mg	0.028 0.056	N05CD04 N05CD04 N05CD01	3 mg 3 mg	9.33 18.67
	Flurazepam Flurazepam	capsule capsule	blister 20 unit(s)	30 mg 15 mg	0.6 0.3	N05CD01	30 mg 30 mg	20 10
	Flurazepam Loprazolam	capsule pill	blister 14 unit(s) blister 15 unit(s)	30 mg 1 mg	0.42 0.015	N05CD01 N05CD11	30 mg 1 mg	14 15
	Lorazepam Lorazepam	pill	blister 60 unit(s) blister 30 unit(s)	2.5 mg 1 mg	0.15 0.03	N05BA06 N05BA06	2,5 mg 2,5 mg 2,5 mg 2,5 mg 2,5 mg	60
	Lorazepam Lorazepam	pill pill	blister 60 unit(s) blister 30 unit(s)	1 mg 2.5 mg	0.06 0.075	N05BA06 N05BA06	2,5 mg	12 24 30
	Lorazepam	pill	bottle 60 unit(s)	5 mg	0.3	N05BA06	2.5 mg	120
	Lorazepam Lorazepam	pill pill	blister 40 unit(s) blister 20 unit(s)	2.5 mg 2.5 mg	0.1 0.05	N05BA06 N05BA06	2,5 mg 2,5 mg	40 20
	Lorazepam Lorazepam	pill pill	blister 20 unit(s) blister 40 unit(s)	1 mg 1 mg	0.02 0.04	N05BA06 N05BA06	2,5 mg 2,5 mg	8 16
	Lorazepam Mexazolam	pill pill	bottle 20 unit(s) blister 60 unit(s)	5 mg 1 mg	0.1	N05BA06 N05BA25	2,5 mg 3 mg	40 20
	Mexazolam	pill	blister 20 unit(s)	1 mg	0.02	N05BA25	3 mg	6.67
	Midazolam Midazolam	coated tablet coated tablet	blister 20 unit(s) blister 14 unit(s)	15 mg 15 mg	0.3 0.21	N05CD08 N05CD08	15 mg 15 mg	20 14
	Oxazepam Oxazepam	pill pill pill	blister 30 unit(s) blister 30 unit(s) blister 60 unit(s)	15 mg 50 mg	0.45	N05BA04 N05BA04	50 mg 50 mg	9 30
	Prazepam	pill	blister 60 unit(s)	10 mg	0.6	N05BA11	30 mg	20
	Prazepam	pill	blister 20 unit(s)	10 mg	0.2	N05BA11	30 mg	6.67

References

- Ait-Daoud, N., A. Hamby, S. Sharma, and D. Blevins, 2018, "A review of alprazolam use, misuse, and withdrawal," Journal of addiction medicine 12 (1): 4.
- American Geriatrics Society, D. M. Fick, T. P. Semla, J. Beizer, N. Brandt, R. Dombrowski, C. E. DuBeau, W. Eisenberg, J. J. Epplin, N. Flanagan, et al. 2015. "American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults." Journal of the American Geriatrics Society 63 (11): 2227–2246.
- Bachhuber, M. A., S. Hennessy, C. O. Cunningham, and J. L. Starrels. 2016. "Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013." American journal of public health 106 (4): 686–688. https://doi.org/10.2105/AJPH.2016.303061.
- Bogowicz, P., H. J. Curtis, A. J. Walker, P. Cowen, J. Geddes, and B. Goldacre. 2021. "Trends and variation in antidepressant prescribing in English primary care: a retrospective longitudinal study." BJGP open 5 (4).
- Boyd, A., S. Van de Velde, M. Pivette, M. Ten Have, S. Florescu, S. O'Neill, J. Almeida, G. Vilagut, J. Haro, J. Alonso, et al. 2015. "Gender differences in psychotropic use across Europe: results from a large cross-sectional, population-based study." European Psychiatry 30 (6): 778–788.
- Buhagiar, K., M. Ghafouri, and M. Dey. 2020. "Oral antipsychotic prescribing and association with neighbourhood-level socioeconomic status: analysis of time trend of routine primary care data in England, 2011–2016." Social Psychiatry and Psychiatric Epidemiology 55 (2): 165–173.
- Caldas de Almeida, J. M., M. Xavier, G. Cardoso, M. G. Pereira, R. Gusmão, B. Corrêa, et al. 2013. "Estudo epidemiológico nacional de saúde mental." Lisboa. Faculdade de Ciências Médicas, da Universidade Nova de Lisboa 1.
- Carrasco-Garrido, P., V. Hernández-Barrera, I. Jiménez-Trujillo, J. Esteban-Hernández, A. Álvaro-Meca, A. López-de Andrés, J. L. DelBarrio-Fernández, and R. Jiménez-Garcia. 2016. "Time trend in psychotropic medication use in Spain: a nationwide population-based study." *International journal of environmental research and public health* 13 (12): 1177.
- Carta, M. G., F. Zairo, G. Mellino, M. C. Hardoy, and E. Vieta. 2006. "An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients." Clinical Practice and Epidemiology in Mental Health 2 (1): 1–4.
- Cipriani, A. 2020. "Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis."
- Cuevas, C. de las, E. Sanz, and J. de la Fuente. 2003. "Benzodiazepines: more" behavioural" addiction than dependence." Psychopharmacology 167 (3): 297–303.
- Ćurković, M., K. Dodig-Ćurković, A. Erić, K. Kralik, and N. Pivac. 2016. "Psychotropic medications in older adults: a review." Psychiatria Danubina 28 (1): 0–24.
- Dai Cao, T.X., L. F. C. Fraga, E. Fergusson, J. Michaud, S. Dell'Aniello, H. Yin, S. Rej, L. Azoulay, and C. Renoux. 2021. "Prescribing Trends of Antidepressants and Psychotropic Coprescription for Youths in UK Primary Care, 2000-2018." Journal of Affective Disorders 287:19–25.
- Dennis, J. A., L. S. Gittner, J. D. Payne, and K. Nugent. 2020. "Characteristics of US adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013–2018." BMC psychiatry 20 (1): 1–6.
- Gardner, D. M. 2014. "Competent psychopharmacology." The Canadian Journal of Psychiatry 59 (8): 406-411.
- Gardner, D. M., A. L. Murphy, S. Kutcher, S. Beaulieu, C. Carandang, A. Labelle, P. Lalonde, A. Malla, H. Milliken, C. O'Donovan, et al. 2013. "Evidence review and clinical guidance for the use of ziprasidone in Canada." Annals of General Psychiatry 12 (1): 1–19.
- Ghiasi, N., R. K. Bhansali, and R. Marwaha. 2021. "Lorazepam." In StatPearls [Internet]. StatPearls Publishing.
- Glantz, M. D., C. Bharat, L. Degenhardt, N. A. Sampson, K. M. Scott, C. C. Lim, A. Al-Hamzawi, J. Alonso, L. H. Andrade, G. Cardoso, et al. 2020. "The epidemiology of alcohol use disorders cross-nationally: Findings from the World Mental Health Surveys." Addictive behaviors 102:106128.
- Gomez, A. F., A. L. Barthel, and S. G. Hofmann. 2018. "Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review." Expert opinion on pharmacotherapy 19 (8): 883–894.
- Hálfdánarson, Ó., H. Zoëga, L. Aagaard, M. Bernardo, L. Brandt, A. C. Fusté, K. Furu, K. Garuoliené, F. Hoffmann, K. F. Huybrechts, et al. 2017. "International trends in antipsychotic use: a study in 16 countries, 2005–2014." European Neuropsychopharmacology 27 (10): 1064–1076. https://doi.org/10.1016/j.euroneuro.2017.07.001.
- Hanlon, J. T., K. E. Schmader, C. Boult, M. B. Artz, C. R. Gross, G. G. Fillenbaum, C. M. Ruby, and J. Garrard. 2002. "Use of inappropriate prescription drugs by older people." *Journal of the American Geriatrics Society* 50 (1): 26–34.
- Hayes, J., P. Prah, I. Nazareth, M. King, K. Walters, I. Petersen, and D. Osborn. 2011. "Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995–2009." *PloS one* 6 (12): e28725.
- $IHME.\ 2019.\ "GBD\ compare\ data\ visualization."\ Institute\ for\ Health\ Metrics\ Evaluation,\ IHME\ Website,\ http://vizhub.health\ data.org/gbd-compare.$
- ______. 2022. "GBD compare data visualization." Institute for Health Metrics and Evaluation, IHME Website, http://vizhub.healthdata.org/gbd-compare.
- Jack, R. H., C. Hollis, C. Coupland, R. Morriss, R. D. Knaggs, D. Butler, A. Cipriani, S. Cortese, and J. Hippisley-Cox. 2020. "Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998–2017: A population-based cohort study." PLoS medicine 17 (7): e1003215.
- Johnson, C. F., B. Williams, S. A. MacGillivray, N. J. Dougall, and M. Maxwell. 2017. "'Doing the right thing': factors influencing GP prescribing of antidepressants and prescribed doses." *BMC family practice* 18 (1): 1–13.
- Kendrick, T., D. Taylor, and C. F. Johnson. 2019. "Which first-line antidepressant?" British Journal of General Practice 69 (680): 114–115.
- Liperoti, R., C. Pedone, and A. Corsonello. 2008. "Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD)." Current Neuropharmacology 6 (2): 117–124.
- Livingston, M. 2020. "Antidepressant prescribing in England: patterns and costs." Prim Care Companion CNS Disord.
- Lockhart, P., and B. Guthrie. 2011. "Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis." *British Journal of General Practice* 61 (590): e565–e572.
- Mancuso, C. E., M. G. Tanzi, and M. Gabay. 2004. "Paradoxical reactions to benzodiazepines: literature review and treatment options." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 24 (9): 1177–1185.

- Marston, L., I. Nazareth, I. Petersen, K. Walters, and D. P. Osborn. 2014. "Prescribing of antipsychotics in UK primary care: a cohort study." BMJ open 4 (12): e006135.
- Mercier, A., I. Auger-Aubin, J.-P. Lebeau, P. V. Royen, and L. Peremans. 2011. "Understanding the prescription of antidepressants: a qualitative study among French GPs." BMC Family Practice 12 (1): 1–9.
- Mercier, A., J. Benichou, I. Auger-Aubin, J.-P. Lebeau, E. Houivet, P. Van Royen, and L. Peremans. 2015. "How do GP practices and patient characteristics influence the prescription of antidepressants? A cross-sectional study." Annals of general psychiatry 14 (1): 1–10.
- Morrens, M., M. Destoop, S. Cleymans, S. Van der Spek, and G. Dom. 2015. "Evolution of First-generation and Second-generation antipsychotic prescribing patterns in Belgium between 1997 and 2012: a population-based study." Journal of Psychiatric Practice® 21 (4): 248–258.
- Murphy, Y., E. Wilson, E. M. Goldner, and B. Fischer. 2016. "Benzodiazepine use, misuse, and harm at the population level in Canada: a comprehensive narrative review of data and developments since 1995." Clinical drug investigation 36 (7): 519–530. https://doi.org/10.1007/s40261-016-0397-8.
- Nuss, P., M. Hummer, and C. Tessier. 2007. "The use of amisulpride in the treatment of acute psychosis." Therapeutics and Clinical Risk Management 3 (1): 3.
- O'Mahony, D., D. O'Sullivan, S. Byrne, M. N. O'Connor, C. Ryan, and P. Gallagher. 2018. "Corrigendum: STOPP/START criteria for potentially inappropriate prescribing in older people: version 2." Age and ageing 47 (3): 489.
- OECD. 2020. OECD Health Statistics 2019. https://www.aeesme.org/wp-content/uploads/2020/09/OECD-2019-Health-at-a-Glance-2019-OECD-Indicators-OECD-Publishing-Paris.pdf.
- OECD and EU. 2018. Health at a Glance: Europe 2018: State of Health in the EU Cycle.
- Prah, P., I. Petersen, I. Nazareth, K. Walters, and D. Osborn. 2012. "National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom." *Pharmacoepidemiology and drug safety* 21 (2): 161–169.
- Ramos, S., D. Cruz, B. Jesus, J. Correia, I. Vaz, and J. Mendes. 2021. "Antipsychotic Polypharmacy and High Doses in a Rural Portuguese Community Mental Health Service." Revista Portuguesa de Psiquiatria e Saúde Mental 7 (3): 109–116.
- Reddy, S., and R. B. Patt. 1994. "The benzodiazepines as adjuvant analgesics." Journal of pain and symptom management 9 (8): 510-514.
- Rosman, S., M. Le Vaillant, and N. Pelletier-Fleury. 2011. "Gaining insight into benzodiazepine prescribing in General Practice in France: a data-based study." BMC Family Practice 12 (1): 1–6.
- Rubio-Valera, M., A. Fernández, J. V. Luciano, C. M. Hughes, A. Pinto-Meza, B. Moreno-Küstner, D. J. Palao, J. M. Haro, and A. Serrano-Blanco. 2012. "Psychotropic prescribing in Catalonia: results from an epidemiological study." *Family Practice* 29 (2): 154–162.
- Saragoussi, D., J. Chollet, S. Bineau, Y. Chalem, and D. Milea. 2012. "Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) study." International journal of clinical practice 66 (11): 1079–1087.
- Saúde, C. N. de. 2019. Sem mais tempo a perder: saúde mental em Portugal-um desafio para a próxima década.
- Semoun, O., and C. Sevilla-Dedieu. 2015. "Psychotropic drug consumption among older people enrolled in a French private health insurance plan." Drugs-Real World Outcomes 2 (3): 217–225.
- Shah, S., I. Carey, T. Harris, S. Dewilde, and D. Cook. 2011. "Antipsychotic prescribing to older people living in care homes and the community in England and Wales." *International journal of qeriatric psychiatry* 26 (4): 423–434.
- Sidorchuk, A., K. Isomura, Y. Molero, C. Hellner, P. Lichtenstein, Z. Chang, J. Franck, L. Fernández de la Cruz, and D. Mataix-Cols. 2018. "Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study." *PLoS medicine* 15 (8): e1002635.
- Silva, M., A. Antunes, S. Azeredo-Lopes, G. Cardoso, M. Xavier, B. Saraceno, and J. M. Caldas-de-Almeida. 2020. "How did the use of psychotropic drugs change during the Great Recession in Portugal? A follow-up to the National Mental Health Survey." *BMC Psychiatry* 20 (1). https://doi.org/10.1186/s12888-020-02620-1.
- Spek, K. van der, D. L. Gerritsen, M. Smalbrugge, M. H. Nelissen-Vrancken, R. B. Wetzels, C. H. Smeets, S. U. Zuidema, and R. T. Koopmans. 2016. "Only 10% of the psychotropic drug use for neuropsychiatric symptoms in patients with dementia is fully appropriate. The PROPER I-study." International psychogeriatrics 28 (10): 1589–1595.
- Stahl, S. M. 2009. "Mechanism of action of trazodone: a multifunctional drug." CNS spectrums 14 (10): 536–546.
- Šubelj, M., G. Vidmar, and V. Švab. 2012. "Time trends in prescribing habits of anxiolytics and antidepressants in Slovenian family practices (with emphasis on elderly patients)." Collegium antropologicum 36 (2): 483–489.
- Sultana, J., D. Italiano, E. Spina, C. Cricelli, F. Lapi, S. Pecchioli, G. Gambassi, and G. Trifirò. 2014. "Changes in the prescribing pattern of antidepressant drugs in elderly patients: an Italian, nationwide, population-based study." European journal of clinical pharmacology 70 (4): 469–478.
- Sundbom, L. T., K. Bingefors, K. Hedborg, and D. Isacson. 2017. "Are men under-treated and women over-treated with antidepressants? Findings from a cross-sectional survey in Sweden." BJPsych bulletin 41 (3): 145–150.
- Svensson, S. A., T. M. Hedenrud, and S. M. Wallerstedt. 2019. "Attitudes and behaviour towards psychotropic drug prescribing in Swedish primary care: a questionnaire study." *BMC family practice* 20 (1): 1–9.
- Tobin, H., G. Bury, and W. Cullen. 2020. "Mental illness in primary care: a narrative review of patient, GP and population factors that affect prescribing rates." Irish Journal of Psychological Medicine 37 (1): 59–66.
- Verhaak, P. F., D. de Beurs, and P. Spreeuwenberg. 2019. "What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? A longitudinal cohort analysis." BMJ open 9 (2): e024051.
- Xu, L., X. Lv, H. Wang, Q. Liu, S. Zhou, S. Gao, X. Yu, S. Deng, S. Wang, Z. Chang, et al. 2021. "Trends in Psychotropic Medication Prescriptions in Urban China From 2013 to 2017: National Population-Based Study." Frontiers in psychiatry, 1472. https://doi.org/10.3389/fpsyt.2021.727453.
- Zangani, C., B. Giordano, H.-C. Stein, S. Bonora, A. D'Agostino, and E. G. Ostinelli. 2021. "Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis." Human Psychopharmacology: Clinical and Experimental 36 (6): e2801.